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Abstract 
Several randomized studies have been completed in prostate cancer that show a benefit to 
immediate  postoperative  treatment  in  patients  undergoing  prostatectomy.  In  one  of  the 
studies, there was even a survival advantage. In spite of those positive findings, there has been 
s o m e   r e l u c t a n c e   t o   u n i f o r m l y   o f f e r   a d j u v a n t   t r e a t m e n t   t o   p a t i e n t s .   T h e   p e r c e p t i o n   i s   t h a t   t h e  
r i s k   i s   n o t   r e a l l y   h i g h   e n o u g h   t o   w a r r a n t   t h e   r i s k   o f   t o x i c i t y   t h a t   c o m e s   w i t h   t r e a t m e n t .   There 
are clearly factors that can help predict who is at the highest risk. Our purpose is to review 
those factors and identify patients that have a high enough risk justifying immediate treatment. 
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Introduction 
T h e   u s e   o f   p o s t   s u r g i c a l   a d j u v a n t   t r e a t m e n t   i n  
o n c o l o g y   i s   c o m m o n .   I n   v i r t u a l l y   e v e r y   d i s e a s e   s i t e ,  
p a t i e n t s   a r e   r o u t i n e l y   o f f e r e d   p o s t   o p e r a t i v e   c h e m o-
therapy, hormonal therapy and/or radiation therapy. 
In many cases, their use is well defined by multiple 
clinical  trials.  While  trials  have  been  performed  in 
p r o s t a t e   c a n c e r   ( p r i m a r i l y   w i t h   t h e   u s e   o f   a d j u v a n t  
radiation therapy)(1-3), there is still much controversy 
a s   t o   t h e   r o u t i n e   u s e   o f   a d j u v a n t   t h e r a p y   a f t e r   p r o s t a-
tectomy. 
T h e   w h o l e   p u r p o s e   o f   a d j u v a n t   t r e a t m e n t   i s   t o  
reduce the risk of morbidity and mortality that would 
come  with  cancer  recurrence.  Prostate  cancer  is 
unique from most other cancers in two ways. First, it 
h a s   a   l o n g   n a t u r a l   h i s t o r y .   I n   g e n e r a l ,   i t   p r o g r e s s e s 
m o r e   s l o w l y   t h a n   m o s t   o t h e r   c a n c e r s .   T h e r e   i s   s e r i o u s  
discussion about whether many prostate cancers need 
t o   b e   t r e a t e d   a t   a l l ,   t h e   p r e m i s e   b e i n g   t h a t   p a t i e n t s   w i l l  
die  of  other  causes  before  the  prostate  cancer  ever 
becomes life threatening (4). The second factor is that 
prostate cancer has a fairly reliable marker in Prostate 
Specific Antigen (PSA). This is truly unique in all of 
oncology. In almost every case, the PSA will rise long 
before  clinical  evidence  of  recurrence  becomes  ma-
nifest  (i.e.  prostate fossa nodule  or  radiographically 
detectable nodal or bone metastasis). With this mark-
er,  there  are  many  that  feel  that  adjuvant  treatment 
can be deferred until the PSA becomes elevated (5) (at 
w h i c h   t i m e   i t   b e c o m e s   s a l v a g e   t r e a t m e n t ) .   T h i s   i s   p u r e  
supposit i o n   a s   t h e r e   a r e   n o   s t u d i e s   d i r e c t l y   c o m p a r i n g  
adjuvant  versus  salvage  treatment,  but  the  thinking 
(and  the  hope)  is  that  PSA  is  sensitive  enough  that 
waiting  for  its  rise  will  not  decrease  any  survival 
benefit of intervention. While there is also controversy 
( 6 )   a b o u t   w h e t h e r   a   r i s i n g   P S A   i s   t r u l y   a   s u r r o g a t e   f o r  
clinical failure with metastasis (which uniformly leads 
t o   d e a t h ) ,   o n e   t h i n g   i s   c e r t a i n - v i r t u a l l y   n o   o n e   d i e s   o f  
p r o s t a t e   c a n c e r   w i t h o u t   a   r i s i n g   P S A .   S o ,   n o   m a t t e r  
h o w   y o u   l o o k   a t   i t ,   a   r i s i n g   PSA is not a good thing if 
you have had your prostate removed for cancer. Also, Journal of Cancer 2011, 2 
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p a t i e n t s   h a v e   a l r e a d y   m a d e   a   d i f f i c u l t   d e c i s i o n   t o  
p r o c e e d   w i t h   a   m a j o r   p r o c e d u r e   w i t h   t h e   p r e m i s e  
t h e y   w i l l   b e   c u r e d   o f   c a n c e r .   F o r   m o s t   p a t i e n t s ,   a   r i s-
ing PSA post prostatectomy  is  a  major  psychological 
blow. (7) 
O u r   u l t i m a t e   g o a l   i s   t o   r e d u c e   t h e   d e a t h   r a t e   o f  
p r o s t a t e   c a n c e r .   S o m e   o f   t h e   a m b i v a l e n c e   a b o u t   t h e  
use of adjuvant treatment is that in patients that un-
d e r g o   c u r a t i v e   s u r g e r y ,   t h e   i m p r e s s i o n   i s   t h a t   v e r y  
few ultimatel y   d i e   o f   p r o s t a t e   c a n c e r   a n d   t h e   r i s k   i s  
s o m e w h a t   m i t i g a t e d   b y   t h e   u s e   o f   s a l v a g e   r a d i a t i o n  
therapy and androgen  ablation.  Therefore  the  argu-
m e n t   i s   m a d e   t h a t   w e   s h o u l d   n o t   r o u t i n e l y   s u b j e c t  
most patients to adjuvant treatment as it is not likely 
to have a major impact on survival and we will have 
s u b j e c t e d   t o o   m a n y   m e n   t o   n e e d l e s s   d a m a g i n g   t r e a t-
ment.  (5)  Still,  it  is  a  failure  of  us  as  physicians  if 
s o m e o n e   d i e s   f r o m   s o m e t h i n g   w e   c o u l d   h a v e   p r e-
vented, especially after having failed to follow a major 
surgical  intervention  with  curative  adjuvant  treat-
ment (curatio interruptus). The fact remains that more 
than 27,000 men (8) die from prostate cancer each year 
and they are coming from somewhere. Since there are 
not many patients that present with metastatic disease 
( ~ 4 % ) ( 9 ) ,   a l m o s t   a l l   o f   t h e   c u r r e n t   p r o s t a t e   c a n c e r  
deaths  are  in  men  that  fail  with  metastatic  disease 
after  primary  intervention.  Therefore  more  than 
2 5 , 0 0 0   m e n   w i l l   s u b s e q u e n t l y   b e   f o u n d   t o   h a v e   m e-
t a s t a t i c   d i s e a s e   a n d   d i e ,   a b o u t   h a l f   o f   w h i c h   w i l l  have 
undergone surgery (9). I f   w e   c o u l d   i d e n t i f y   t h o s e   p a-
t i e n t s ,   i t   w o u l d   m a k e   t h e   d e c i s i o n   a b o u t   a d j u v a n t  
treatment relatively easy.  
At the same time, if we had effective, inexpen-
s i v e   a d j u v a n t   t h e r a p y   t h a t   h a d   n o   o r   m i n i m a l   m o r-
bidity, it would also make for an easier decision. Of 
course, neither of those conditions exists, so it really 
comes  down  to  compromises  and  trade  offs  in  the 
t e r m s   o f   r i s k   a n d   b e n e f i t s .   T h e   r e m a i n d e r   o f   t h i s   d i s-
cussion is to how we identify patients with enough 
r i s k   t h a t   w e   s h o u l d   seriously  consider  adjuvant 
t r e a t m e n t .   I f   w e   c a n   i d e n t i f y   t h o s e   p a t i e n t s ,   i t   i s   o n l y  
half the discussion with the remaining consideration 
b e i n g   t h e   e f f i c a c y   a n d   t o x i c i t y   o f   t h e   a d j u v a n t   t r e a t-
ment. 
PSA as a predictor of mortality 
T h e r e   a r e   s o m e   t h i n g s   w e   d o know. The cause of 
death from prostate cancer is from metastatic disease 
and metastatic disease is not curable. We can delay 
the inevitable death with androgen ablation (10)( for 
about 2 years) and with chemotherapy (11) (for about 
1   m o n t h ) ,   b u t   u n l e s s   t he patients are “lucky” enough 
t o   d i e   f r o m   s o m e t h i n g   e l s e   i n   t h e   i n t e r i m ,   t h e y   w i l l  
ultimately  die  from  the  cancer.  Once  metastatic  dis-
ease develops, the race is on, and there is no winner. 
Therefore, the development of metastatic disease is a 
fair  endpoint   i n   t h e   e v a l u a t i o n   o f   p r o s t a t e   c a n c e r  
mortality  and  the  prevention  of  metastasis  is  a  rea-
sonable goal. 
I t   i s   a l s o   a   f a c t   t h a t   n o   o n e   ( v i r t u a l l y )   d e v e l o p s  
metastatic disease dies of prostate cancer without an 
elevated PSA. As a result, there is a real temptation to 
u s e   P S A   a s   a   s u r r o g a t e   f o r   p r o s t a t e   c a n c e r   o u t c o m e .  
This is made more compelling by the fact that it is 
universally  obtained  in  patients  post  prostatectomy 
a n d   i t   i s   a   h a r d   n u m b e r - it is not quite as subjective as 
trying to interpret a bone or CT scan. Also, patients 
a r e   t u n e d   i n t o   t h e   i m p l i c a t i o n s   o f   a   r i s i n g   P S A ,   s o   i t   i s  
very difficult to dismiss it after the fact. Of course, the 
dilemma is that there can be a long interval between a 
rising  PSA  and  metastasis/death.  In  the  famous 
Hopkins  study  ( 1 2 ) ,   i n   a   s u b g r o u p   o f   p a t i e n t s   t h a t  
weren’t  offered  treatment  at  the  time  of  initial  PSA 
r i s e ,   i t   t o o k   a   m e d i a n   o f   8   y e a r s   ( 3 7 %   a t   5   y e a r s )   f o r  
metastatic disease to manifest itself and a median of 5 
y e a r s   f o r   t h e m   t o   d i e .   P r e s u m a b l y ,   t h e y   r e c e i v e d   a n-
drogen ablation at the time of metastatic disease. It is 
worth noting that every patients with metastatic dis-
ease died of prostate cancer, so if the PSA failure was 
p r e v e n t e d   ( i f   i t   w a s   p o s s i b l e ) ,   t h e y   w o u l d   n o t   h a v e  
d i e d   o f   c a n c e r .   A l s o ,   e v e n   t h o u g h   n o t   e v e r y one  de-
veloped metastatic disease at the time of analysis, the 
metastasis  free  survival  curve  has  an  unwavering 
d o w n w a r d   s l o p e   t h a t   i f   i t   c o n t i n u e s   a s   i s ;   e v e r y   p a-
t i e n t   w i l l   h a v e   m e t a s t a t i c   d i s e a s e   o r   b e   d e a d   b y   2 0  
y e a r s .   O f   c o u r s e ,   n o t   e v e r y o n e   w i l l   d i e   o f  cancer  as 
long as they die of something else first, and, in an 
aging  population,  it  is  a  real  possibility.  It  is  this 
g r o u p   t h a t   c o m p l i c a t e s   t h e   s i t u a t i o n   a s   w e   d o   n o t  
want  to  offer  potentially  morbid  treatment  to  men 
t h a t   d o n ’ t   r e a l l y   n e e d   i t .   T h e r e   i s   n o good solution for 
t h i s   d i l e m m a .   I n   t h e i r   s t u d y ,   t h e   H o p k i n s   r e s e a r c h e r s  
tried to identify factors unique to the patients devel-
o p i n g   m e t a s t a t i c   d i s e a s e   s o o n e r   t h a n   l a t e r .   T h e y  
f o u n d   t h a t   G l e a s o n   s c o r e ,   t h e   t i m e   f r o m   s u r g e r y   t o  
recurrence and PSA doubling time predict for earlier 
metastatic disease. Unfortunately, if you wait for the 
PSA to declare itself, you are already behind the curve 
when it comes to intervention, especially in what is 
obviously  a  more  virulent  cancer.  Dilemmas  aside, 
one fact remains: in spite of the long natural history, 
t h e   s t u d y   d o e s   s h o w   u s   t h a t   i n   m e n   w i t h   a   r i s i n g   p o s t  
p r o s t a t e c t o m y   P S A   u l t i m a t e l y   a l l   o f   t h e m   w i l l   d e v e l o p  
metastatic disease, 70% of them by 10 years and that 
d i s e a s e   w i l l   b e   f a t a l .   T h e r e   i s   n o   d e n y i n g   t h a t   p o s t  
prostatectomy rising PSA is an enormously powerful 
predictor of metastatic disease. Therefore, in using the 
risk of PSA failure as an indicator of patients that are Journal of Cancer 2011, 2 
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at also at a high risk for metastasis and death is not 
unreasonable. The highest risk patients are those that 
have a high incidence of biochemical failure and do so 
in the first couple of years. 
Risk warranting intervention 
In identifying patients at high risk for failure, 
P S A   i s   n o t   o n l y   a   m a r k e r   of recurrence, but is also one 
of the three most widely accepted prognostic markers 
for r e c u r r e n c e   i n   p r o s t a t e   c a n c e r .   T h e   o t h e r   t w o   a r e  
grade (usually in the form of Gleason score) and stage 
(with  pathological  stage  being  more  accurate  than 
clinical stage). A s   n o t e d   a b o v e ,   P S A   i s   t h e   l e a s t   s u b-
j e c t i v e .   A l t h o u g h   t h e r e   i s   l a b   v a r i a t i o n ,   t h e r e   i s   c o n-
sistency  and  a  number  is  more  definite.  Regarding 
grade, before the 1980’s, as with most cancers, nuclear 
g r a d e   w a s   h o w   p r o s t a t e   c a n c e r   w a s   g r a d e d .   T h i s   h a s  
now been s u p p l a n t e d   b y   t h e   G l e a s o n   s c o r i n g   s y s t e m  
w h i c h   e n c o m p a s s e s   n o t   o n l y   t h e   f e a t u r e s   o f   g r a d e ,   b u t  
t h e   m o r p h o l o g y   o f   t h e   c a n c e r .   I t   h a s   b e c o m e   u b i-
q u i t o u s   i n   u r o l o g i c   o n c o l o g y   t o   t h e   p o i n t   w h e r e   i t   i s  
u s u a l l y   t h e   o n l y   g r a d e   r e p o r t e d .   I t   i s   s u b j e c t i v e   a s   i t  
requires the pathologist to score the appearance of the 
cancer.  The  concordance  between  those  specializing 
in urologic pathology is no better than 70 %. (13) Also, 
t h e   G l e a s o n   s c o r e   o f   t h e   p r o s t a t e   b i o p s y   i s   o n l y   a   r e l-
ative  representation  of  that  in  the  final  pathologic 
specimen  from  the  prostatectomy.  Exact  correlation 
between the biopsy and prostatectomy Gleason score 
o c c u r s   o n l y   a b o u t   5 0 %   o f   t h e   t i m e   ( 1 4 )   a n d   c l e a r l y   t h e  
l a r g e r   v o l u m e   o f   t i s s u e   i n   a   p r o s t a t e c t o m y   s p e c i m e n  
allows for a more definitive determination. Staging is 
also greatly improved by being able to evaluate the 
prostatectomy  specimen.  Although  there  is  some 
correlation between clinical stage and outcome, clini-
cal staging is fairly subjective. Although subject to the 
variations of methodology, pathologic staging, (espe-
cially the details about margins), seminal vesicle in-
volvement and lymph node involvement, provides a 
l o t   m o r e   s p e c i f i c   i n f o r m a t i o n   a n d   i s   m u c h   m o r e   p r e-
ferred in risk analysis than clinical staging. While each 
of the prognostic triad is independently predictive of 
outcome, as we will discuss later the three together 
are much more powerful than any one of them indi-
vidually. 
 A s   d i s c u s s e d   a b o v e ,   t h e   H o p k i n s   d a t a   w o u l d  
indicate that patients with a post prostatectomy rising 
PSA if left untreated have a metastasis rate of 70% by 
1 0   y e a r s . ( 1 2 )   T h i s   i s   s u p p o r t e d   b y   t h e   d a t a   f r o m   t h e  
SWOG study where for the observation group (noting 
that  >30%  subsequently  received  radiation  and/or 
androgen ablation), 56% suffered biochemical failure 
by  5  years,  which  translated  into  a  metastasis  free 
s u r v i v a l   o f   6 0 %   a t   1 0   y e a r s   a n d   4 0 %   a t   1 5   y e a r s .   A c-
counting  for  the  salvage  treatment  in  the  SWOG 
group, this is remarkably similar to the Hopkins data 
(which  excluded  patients  receiving  salvage  therapy 
that had a durable response). Further, in the SWOG 
study,  the  overall  survival  difference  between  the 
observation group and the immediate adjuvant radi-
ation therapy group was 8% at 10 years and 11% at 15 
years. (1) Cause specific survival was not delineated, 
but it would appear that this ~10% difference in sur-
v i v a l   w a s   d u e   t o   u n c o n t r o l l e d   c a n c e r .   T h a t   w o u l d  
mean that the 56% 5 year biochemical failure rate in 
the  observation  patients  not  only  translates  into  at 
least a 17% metastasis rate (15), but also ~10% cancer 
d e a t h   r a t e   b y   1 0   y e a r s .   T h i s   i s   c o n s e r v a t i v e   g i v e n   t h a t  
t h e   r a d i a t i o n   d i d   n o t   c u r e   e v e r y o n e   i n   t h e   c o m p a r a-
tive  group  (for  example,  the  metastasis  incidence 
dropped for 17% to 8% with radiation, not to 0). Fur-
t h e r   e v i d e n c e   c o m e s   f r o m   a n o t h e r   s t u d y   w i t h   2 65 
prostatectomy  patients  that  suffered  a  biochemical 
r e c u r r e n c e   a n d   1 7 %   o f   t h e m   d i e d   o f   c a n c e r   w i t h   a  
m e d i a n   f o l l o w   u p   o f   1 0   y e a r s ,   e v e n   w i t h   s a l v a g e  
t r e a t m e n t s .   ( 1 6 ) .   A s   w o u l d   b e   e x p e c t e d ,   n o n e   o f   t h e  
448 patients without biochemical failure died of can-
ce r .   O n e   p a t h o l o g i c   s u b g r o u p   h a d  a 63% PSA failure 
rate,  suffering  a  10%  death  rate  from  cancer  and 
another group had an 88% biochemical failure rate 
r e s u l t i n g   i n   a   3 4 %   c a n c e r   d e a t h   r a t e .   T h e   e x a c t   s a m e  
prostate cancer death incidence (17%) was reported in 
a   s t u d y   o f   3 7 9   m e n   w i t h   b i o c h e m i c a l   f a i l u r e   a f t e r  
prostatectomy  (17).  Taken  together,  these  different 
studies  would  indicate  that  patients  with  a  50-60% 
biochemical failure rate have at least a 10% risk of 
d y i n g   o f   p r o s t a t e   c a n c e r   a n d   t h e   h i g h e r   t h e   r i s k   o f 
biochemical  failure,  the  higher  the  risk  of  cancer 
d e a t h .   S o ,   w e   w o u l d   a r g u e   t h a t   t h e   p l a c e   t o   s e r i o u s l y  
consider adjuvant treatment is in patients that have a 
biochemical failure rate of greater than 50-60%. This is 
actually  conservative.  In  clinical  trial  design,  some 
have  designated  patients as  high  risk of  recurrence 
(warranting  neoadjuvant  chemotherapy)  if  the  no-
mogram predicted risk of failure was >40% by 5 years 
( 1 8 ) .   O t h e r s   h a v e   p r o p o s e d   t h a t   p a t i e n t s   w i t h   a   b i o-
c h e m i c a l   f a i l u r e   r a t e   o f   2 5 -35% are appropriate can-
didates for adjuvant local therapy (19). Given that, we 
would argue that our threshold is reasonable and that 
patients with < 50% 5 year biochemical control have a 
high enough risk of metastasis and death to warrant 
serious consideration of adjuvant treatment. 
Seminal vesicle and lymph node positive 
The determination of risk is not straightforward. 
As  discussed  earlier,  the  three  standard  prognostic 
factors are Gleason score, PSA and stage. There are 
subgroups in each that appear to have a ver y   h i g h   r i s k  Journal of Cancer 2011, 2 
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o f   r e c u r r e n c e .   S o   t h e   f i r s t   p l a c e   t o   s t a r t   i s   w h e t h e r  
t h e r e   a r e   a n y   s i n g l e   f a c t o r s   t h a t   p o r t e n d   s u c h   a   g r e a t  
risk that they alone would indicate the need for ad-
juvant treatment. One that easily falls into this cate-
gory is that of positive lymph node metastasis. The 
r i s k   o f   f a i l u r e   i n   t h e s e   p a t i e n t s   i s   n o n -controversial 
a n d   w e   w o n ’ t   d i s c u s s   i t   f u r t h e r .   W e   w o u l d   s u b m i t  
t h a t   t h e   s e c o n d   o f   t h e s e   i s   t h a t   o f   s e m i n a l   v e s i c l e   i n-
volvement, which has been extensively studied (Table 
1).   
 
Table 1. Effect of seminal vesicle involvement on failure 
SV                 
Study  # pts  PSA 
Failure 
Months 
Med f/u 
(mean) 
modifiers  Failure rate  5 yr DFS  7 yr DFS  10 yr DFS 
Swanson16  35  >0.3  121  EPE- mar-  60%  47%    33% 
9  EPE+mar-  75%  33%    17% 
19  EPE+mar+  95%  10%    0% 
Han22  113  >0.2  76      48%  30%  17% 
Roehl24  NS  > 0.3  (65)          26% 
Trapasso27  93  >0.4  34      40%     
Sofer 29  10  >0.3  43   Gl 2-6  40%       
30  Gl 7  47%       
26  Gl 8-10  58%       
18  Cap pen  67%       
41  EPE  49%       
34  Mar+  56%       
Stephenson30  195  > 0.2 x2  38  Mar+      21%   
224      Mar-      48%   
 Karakiewicz31  352  0.1-0.4  25  Mar-    43%    20% 
300      Mar+    19%    12% 
 Hull 32  81  0.4  47      37%    37% 
Salomon33  137  >0.2  (59)    52%  34%    10% 
 
 
D’Amico 34 
  PSA*       
0-4  20-50 
70 
NS 
>0.1  42*  Gl 
8-10 
Mar-  66%  96%       
Mar +  89%  99%       
Gl 
7 
mar-  55%  91%       
Mar+  79%  99%       
Gl 
5-6 
mar-  51%  88%       
Mar+  76%  99%       
Gl 
2-4 
mar-  36%  74%       
Mar+  59%  93%       
 Quinn 35  79  >0.4  39 (41)    30%       
Tefilli 36  59  >0.4  43   Mar+    14%     
34  Mar-    49%     
70  PSA<10    59%     
23  PSA>10    17%     
8  Gl <7    45%     
85  Gl>7    22%     
Freedland 37  135  > 0.2 x2  32      36%     
80  Mar +    21%     
55  Mar -    56%     
Definition of failure and disease free survival: based on biochemical (PSA) failure and includes biopsy proven local recurrence and radio-
logically detected distant metastasis 
* 2 year endpoint for all groups. Mar+ is margin positive; Mar- is margin negative; EPE+ is extraprostatic extension present; EPE- is extra-
prostatic extension absent; foc is focal; Ext is extensive; Est is established; Gl is Gleason score 
 
There were several concurrent reports from John 
Hopkins  that  included  seminal  vesicle  positive  pa-
tients  (SV+) with  differing  follow up and  selection 
criteria. In an early study, (20) there was no difference 
in  failure  between  SV+ and  LN+  patients  and  they 
w e r e   g r o u p e d   t o g e t h e r   w i t h   t h e   f i n d i n g   o f  a 5 and 10 
year failure free survival of 37% (63% failure rate) and 
1 3 % ,   r e s p e c t i v e l y .   I n   a   l a r g e r   s t u d y   f r o m   t h e   s a m e  
year (21), 2091 patients were followed for a median of 
5.9  years.  On  multivariate  analysis,  Gleason  score, 
preoperative PSA and whether organ confined (ver-
s u s   e x t r a p r o s t a t i c   o r   l y m p h   n o d e   p o s i t i v e )   w ere sig-
nificant  factors  for  recurrence.  Among  factors  that 
were not predictive were margin status and seminal Journal of Cancer 2011, 2 
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vesicle  involvement.  In  this  cohort,  it  appears  that 
extraprostatic  extension  (EPE)  alone  was  a  strong 
enough  predictor  that  no  additional  prognostic  in-
f o r m a t i o n   w a s   r e a l i z e d   f r o m   t h e   s e m i n a l   v e s i c l e   s t a-
tus. In yet another large study from the same institu-
tion (22) with a slightly longer mean follow up of 6.3 
years, 17% of the patients had failed (PSA >0.2). For 
t h e   S V +   p a t i e n t s ,   5   y e a r   d i s e a s e   f r e e  survival was 48%, 
dropping  to  30%  by  10  years  and  17%  by  15  years. 
( T a b l e   1 ) .   F i n a l l y ,   i n   a   m o r e   r e c e n t   v e r s i o n ,   ( 2 3 )   s e-
minal vesicle positive patients had a 75% biochemical 
failure rate and 23% death rate by 12 years. From all 
t h e s e   s t u d i e s ,   i t   a p p e a r s   t hat although seminal vesicle 
involvement is not always a driving predictive factor 
(as  evidenced  by  the  multivariate  analysis  in  the 
m i d d l e   s t u d y ) ,   i t   i s   c l e a r   t h a t   t h e i r   S V   p o s i t i v e   p a t i e n t s  
have a very high risk of failure.  
Obviously,  failure  risk  will  be  determined  by 
length of follow up. In a study with relatively long 
f o l l o w   u p   ( 6 5   m o n t h s )   ( 2 4 ) ,   e v e n   t h o u g h   s o m e   o f   t h e  
patients received adjuvant radiation therapy, for SV 
positive patients, the 10 year disease free survival rate 
was  26  %. (T a b l e   1 ) .   I n  an earlier more detailed de-
s c r i p t i o n   ( 2 5 )   o f   s o m e   o f   t h e   s a m e   p a t i e n t s ,   c o n s i d e r-
ing the factors of grade, PSA and pathological stage, 
t h e   m o s t   f a v o r a b l e   p a t i e n t s   w i t h   p o s i t i v e   s e m i n a l   v e-
sicles had a PSA <10 ng/ml and well differentiated 
tumors resulting in   a   7   y e a r   d i s e a s e   f r e e   s u r v i v a l   o f  
61%. For those with moderately differentiated cancer, 
i t   d r o p p e d   t o   4 6 %   a n d   f o r   t h e   p o o r l y   d i f f e r e n t i a t e d  
3 3 % .   I f   t h e   P S A   w a s   > 1 0   n g / m l ,   a l l   t h r e e   g r o u p s   d i d  
m u c h   w o r s e   ( 2 5 % ,   1 1 % ,   a n d   5 % ,   r e s p e c t i v e l y ) .   I n   a  
study with even longer follow up (121 months) lymph 
node positive patients were excluded (16) and 37% of 
the entire cohort recurred (PSA >0.3). For SV positive 
patients, overall 73% failed and 28% died of cancer, 
w h i c h   i n c r e a s e d   t o   8 8 %   a n d   3 4 %   i f   t h e y   a l s o   h a d   e x-
traprostatic disease (EPE). 
N u m e r o u s   s t u d i e s   h a v e   r e p o r t e d   5   y e a r   c o n t r o l  
rates  in  the  40-6 0 %   r a n g e   f o r   S V   p o s i t i v e   p a t i e n t s ,  
i n f l u e n c e d   b y   l e n g t h   o f   f o l l o w   u p ,   u s e   o f   a d j u v a n t  
treatment and other defining factors; 52% (26), 40% 
(27),  and  36%  (Gleason  8-10)(28).  Several  studies 
s i m p l y   d e s c r i b e d   t h e   f a i l u r e   r a t e .   I n   o n e   ( 2 9 )   w i t h   1 0 6  
SV positive patients, with a median follow up of 43 
months, for Gleason 2-6, 40% failed; Gleason 7, 47%; 
and  Gleason  8-10,  58%.  Another  (19)  found  that 
Gleason 8-10 and SV+ patients had a very high 7 year 
failure rate (72%), which was slightly improved if the 
PSA was < 10 ng/ml (63%) versus >10 ng/ml (86%). 
There  have  been  two  large  pooled  studies  of 
radical  prostatectomy  patients.  Unfortunately,  the 
follow up is relatively short and many patients were 
e x c l u d e d   f o r   v a r i o u s   r e a s o n s .   I n   t h e   f i r s t   ( 3 0 )   w i t h   3  
institutions, 419 seminal vesicle positive patients were 
i d e n t i f i e d   w i t h   a   m e d i a n   f o l l o w   u p   o f   3 8   m o n t h s .  
Those that had negative margins had a 48% 5 year 
disease  free  survival  and  for margin positive, 21%. 
The other large pooled analysis (31) resulted in 352 SV 
positive patients, but with a median follow up of only 
25 months. On multivariate analysis, significant fac-
tors for recurrence were PSA, Gleason score, margin 
status, EPE, and SV involvement. SV positive patients 
with positive margins had a 5 and 10 year failure free 
survival  of  only 19% and 12% respectively and for 
negative margins 43% and 20%, respectively. One of 
the  participating  institutions  (32)  reported  on  their 
own  cohor t ,   b u t   w i t h   l o n g e r   f o l l o w   u p   ( m e d i a n   4 7  
months). Fifteen percent of the patients failed (PSA 0.4 
n g / m l )   f o r   a   1 0   y e a r   f a i l u r e   f r e e   s u r v i v a l   o f   7 5 % .   A s  
with  the  multi-institutional  study,  on  multivariate 
a n a l y s i s ,   G l e a s o n   s c o r e ,   E P E ,   m a r g i n   s t a t u s   a n d   S V  
status were predictive. For SV positive patients, 5 and 
1 0   y e a r   d i s e a s e   f r e e   s u r v i v a l   w e r e   b o t h   3 7 % .   T h e   1 0  
year metastasis free survival was 57%. In a smaller 
combined study (33), 137 SV positive patients were 
f o l l o w e d   f o r   a   m e d i a n   o f   4 . 9   y e a r s .   F i f t y   t w o   percent 
f a i l e d   ( P S A   > 0 . 2   n g / m l )   r e s u l t i n g   i n   a   1 0   y e a r   p r o-
gression free survival of 10%. On multivariate analy-
sis, PSA and Gleason were predictive of failure, but 
E P E   a n d   m a r g i n   s t a t u s   w e r e   n o t .   A   m o r e   a g g r e s s i v e  
a p p r o a c h   ( 3 4 )   t o   p a t i e n t   s e l e c t i o n   w a s   t o   l ook at the 2 
year failure rate with supposition they would be more 
likely to develop metastatic disease. With that suppo-
s i t i o n ,   i t   w a s   p r o p o s e d   t h a t   a   2   y e a r   f a i l u r e   r a t e   o f  
>50% was certainly enough to warrant adjuvant in-
tervention. Almost all the SV positive patients fell into 
t h a t   c a t e g o r y .   I t   m i g h t   b e   p o s s i b l e   t o   t e a s e   o u t   p a t i e n t s  
that don’t need treatment, but in this study, the lowest 
r i s k   p a t i e n t s   ( P S A   < 4   n g / m l ,   G l e a s o n   2 -6 and margin 
negative) still had a 2 year failure rate of 36%. 
A s   n o t e d   f r o m   T a b l e   1 ,   t h e   f a i l u r e   r a t e   f o r   S V  
positive  cancer  is  high,  although  there  are  series 
w h e r e   i t   i s   n o t   s o   d i r e   ( 3 5 ) .   U n d o u b t e d l y ,   t h e s e   v a r i a-
tions are from the presence of other mitigating factors. 
A s   n o t e d   i n   s o m e   o f   t h e   s t u d i e s   c i t e d   a b o v e ,   s o m e  
f a c t o r s   m i g h t   b e   a b l e   t o   b e t t e r   d e f i n e   w h o   w i l l   f a i l .  I n   a  
s t u d y   ( 3 6 )   o f   9 3   S V   p o s i t i v e   p a t i e n t s ,   5 7 %   r e c u r r e d .  
F i v e   y e a r   d i s e a s e   f r e e   s u r v i v a l   w a s   1 7 %   f o r   P S A   >   1 0  
ng/ml, 22% for Gleason >7 and 14% for margin posi-
t i v e   p a t i e n t s ,   c o m p a r e d   t o   5 9 %   f o r   P S A   <   1 0   n g / m l ,  
45% for Gleason < 7 and 49% for negative margin. In a 
s i m i l a r   s t u d y   ( 3 7 )   o f  135 SV positive patients, 5 year 
progression  free  survival  was  36%.  If  the  margins 
w e r e   p o s i t i v e ,   i t   d r o p p e d   t o   2 1 % ,   b u t   i f   n e g a t i v e ,  
slightly better at 56%. In 19 patients that had Gleason 
2-6 cancer with negative margins, the 5 year disease 
f r e e   s u r v i v a l   w a s   6 9 % ,   w h i c h   w a s   s i m i l a r   t o   t h e   S V  Journal of Cancer 2011, 2 
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negative  patients.  For  the  11  patients  in  that  group 
less than 60 years of age, there were no failures. Fi-
n a l l y ,   ( 3 8 )   t h e   l o w e s t   r i s k   w a s   f o r   p a t ients with Glea-
son <7 and PSA <10 ng/ml, with a 75% 34 month 
d i s e a s e   f r e e   s u r v i v a l .   F o r   G l e a s o n   7   p a t i e n t s   i t   w a s  
o n l y   5 4 % .   T h e s e   s t u d i e s   s u g g e s t   t h a t   i t   m i g h t   b e  
possible to try to select out patients that may not have 
as high a risk of failure. One more complex attempt to 
do this was using Gleason score and the percentage of 
biopsy cores as a discriminator (39) A 2 year failure 
rate was chosen as previous observations indicated 
that patients failing in the first two years were highly 
likely (>50%) to develop  metastatic  disease  by  five 
y e a r s .   F o r   S V   p o s i t i v e   G l e a s o n   8 -10 patients all the 
patients (any PSA, any margin status) had at a 2 year 
f a i l u r e   r i s k   o f   a t   l e a s t   5 0 %   e x c e p t   f o r   p a t i e n t s   w i t h  
both PSA < 20 ng/ml. and <34% biopsy positivity. All 
t h e   S V   p o s i tive Gleason 7 patients had >50% 2 year 
f a i l u r e   r a t e   e x c e p t   t h o s e   w i t h   P S A   < 2 0   n g / m l   a n d  
m a r g i n s   n e g a t i v e   a n d <   3 4 %   p o s i t i v e   c o r e s .   T h e   p a-
tients in that group (Gleason 7, margin negative) with 
34-50% positive cores had a 2 year recurrence rate of 
40-47%. The  great  caution  here  is  that  although  the 
e x a c t   p a t i e n t   n u m b e r s   f o r   e a c h   o f   t h e   s u b g r o u p s   w a s  
n o t   r e p o r t e d ,   w i t h   t h i s   m a n y   s u b g r o u p s ,   i t   i n v a r i a b i l-
ity got very small, likely down to 1-2  patients. This 
w o u l d   b e   e s p e c i a l l y   t r u e   i n   t h e   l o w e r   g r a d e   p a t i e n t s   a s  
low Gleason scores are uncommon in seminal vesicle 
positive patients. So, for the Gleason 2-6 patients with 
P S A   l e s s   t h a n   1 0   n g / m l . ,   w h i l e   t h e r e   w a s  no subgroup 
with  a  greater  than  45%  2  year  failure,  great  care 
s h o u l d   b e   t a k e n   b e f o r e   u s i n g   t h i s   d a t a   a s   a  reason not 
t o   t r e a t .   O f   c o u r s e ,   t h e s e   c a u t i o n s   a r e   t r u e   f o r   m o s t  
retrospective  data,  especially  those  that  divide  the 
d a t a   d o w n   t o   v e r y   s m a l l   s p e c i f i c   s u b g r o u p s .   T h e   b u l k  
o f   t h e   d a t a   w o u l d   i n d i c a t e   t h a t   s e m i n a l   v e s i c l e   p o s i-
tive patients have a significant r i s k   o f   f a i l u r e   a n d   t h a t  
adjuvant therapy is warranted. 
The limitations of the small numbers of patients 
in the more favorable subgroups make selecting those 
patients for avoidance of intervention a risky propo-
sition. In a subgroup analysis of the SWOG adjuvant 
study (also with small numbers), all the subgroups 
benefitted from adjuvant radiation to the same degree 
(40). 
Gleason score 
Gleason score is also highly prognostic. Patients 
a r e   u s u a l l y   g r o u p e d   b y   G l e a s o n   s c o r e   < 7   n g / m l   ( l o w  
risk), 7 ng/ml ( i n t e r m e d i a t e   r i s k )   a n d   > 7   n g / m l   ( h i g h  
r i s k ) .   G l e a s o n   7   i s   f r e q u e n t l y   c o m b i n e d   w i t h   G l e a s o n  
8-1 0   w h e n   t h e   f i n d i n g s   i n d i c a t e   a   c o m p a r a b l e   r i s k  
(16,41) While the findings for Gleason 7 is somewhat 
variable, there is little question that Gleason 8-10 pa-
tients h a v e   a   h i g h   r i s k   o f   f a i l u r e .   T h i s   d a t e s   b a c k   t o  
some of the earliest prostatectomy series. In a perineal 
prostatectomy population in the pre-PSA  era,  failure 
was defined as clinical (biopsy proven local failure or 
distant metastasis or an elevated prostatic acid phos-
phatase)  (42).  Lymph  node  positive  patients  were 
excluded,  but  not  seminal  vesicle  positive  patients. 
Even with adjuvant radiation in approximately 65% of 
the patients, those with Gleason 8-10 cancer had a 5 
year clinical failure rate of 57% and 10 year rate of 
80%. In another series of perineal prostatectomy pa-
t i e n t s   ( 4 3 ) ,   w i t h   f a i l u r e   d e f i n e d   a s   a   P S A   o f   > 0 . 5  
n g / m l ,   G l e a s o n   8 -1 0   p a t i e n t s   h a d   a   f a i l u r e   r a t e   o f   6 9 % .  
A s   n o t e d   p r e v i o u s l y ,   t h e   H o p k i n s   g r o u p   h a s  
published various evaluations of their prostatectomy 
s e r i e s   a n d   a s   w i t h   t h e   e f f e c t   o f   p o s i t i v e   s e m i n a l   v e-
s i c l e s   t h e y   h a v e   a l s o   e v a l u a t e d   G l e a s o n   s c o r e .   I n  
e v a l u a t i o n   o f   t h e   e n t i r e   c o h o r t   ( 2 1 )   w i t h   a   m e d i a n  
f o l l o w   u p   o f   5 . 9   y e a r s ,   1 7 %   o f   t h e   p a t i e n t s   f a i l e d   f o r   a  
5, 10, and 15 year biochemical recurrence free survival 
of 84%, 72% and 61% respectively. Gleason score was 
the  most  strongly  predictive  factor  for  failure.  For 
p a t i e n t s   w i t h   a   G l e a s o n   s c o r e   o f   8 -1 0 ,   w i t h   P S A   0 -4 
ng/ml, by 5 years, 56% had failed (79% by 10 years), 
with  PSA  4.1-10  ng/ml   6 3 %   ( 8 5 % ) ,   f o r   P S A   1 0 . 1 -20 
ng/ml 69% (89%) and for PSA >20 ng/ml 75% (93%). 
Noteworthy is that for patients with Gleason 7 (4+3) 
c a n c e r   w i t h   a   P S A   o f   4 . 1 -10 ng/ml and 10.1-20 ng/ml 
failure rate at 10 years was 58% and 69%, respectively. 
F o r   P S A   > 2 0 ,   a t   5  years it was 57% and at 10 years it 
was 80%. In a later update (22) with slightly longer 
f o l l o w   u p   ( m e a n   6 . 3   y e a r s ) ,   t h e   f a i l u r e   r a t e   o v e r a l l   f o r  
their  prostatectomy  patients  was  still  17%.  For  the 
Gleason  8-10  patients,  10  year  disease  free  survival 
was  29%,  which  dropped  to  15%  by  15 years. For 
G l e a s o n   4 + 3   p a t i e n t s ,   1 0   a n d   1 5   y e a r   d i s e a s e   f r e e   s u r-
vival was 33%. In a study of some of the same patients 
( 4 4 ) ,   b u t   w i t h   e x c l u s i o n   o f   t h e   h i g h e s t   r i s k   p a t i e n t s  
( l y m p h   n o d e   a n d   s e m i n a l   v e s i c l e   p o s i t i v e   a n d   t h o s e  
with adjuvant androgen ablation or radiation), with a 
m e d i a n   f o l l o w   u p   o f   6   y e a r s ,   f o r   G l e a s o n   8 -9, 5 and 10 
year progression free survival 59% and 35%, respec-
tively. These findings are fairly consistent across stu-
dies.  In  one  study  (45),  patients  with  Gleason  8-10 
cancer had less than 30% 5 year disease free survival. 
T h i s   i m p r o v e d   w i t h   s u b s e q u e n t   f o l l o w   u p   f r o m   t h e  
same  institution  (32).  For  38  Gleason  8-10  patients 
w i t h   a   m e d i a n   f o l l o w   u p   o f   4 7   m o n t h s ,   5   a n d   1 0   y e a r  
disease free survival was 49% and 41%, respectively. 
T h e   1 0   y e a r   m e t a s t a s i s   f r e e   s u r v i v a l   w a s   5 8 % .   I n  
another study (24) with somewhat longer follow up 
(mean 65 months), even though some of the patients 
received adjuvant radiation therapy, for Gleason 8-10 
p a t i e n t s ,   t h e   1 0   y e a r   d i s e a s e   f r e e   s u rvival  rate  was Journal of Cancer 2011, 2 
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32%. For Gleason 4+3 patients it was 50%. In another 
study (26) that included adjuvant treatment, Gleason 
8-1 0   p a t i e n t s   h a d   a   5   y e a r   P S A   r e c u r r e n c e   f r e e   s u r-
v i v a l   o f   4 3 % .   I n   a   f o l l o w   u p   s t u d y   f r o m   t h e   s a m e   i n-
stitution  (46)  with  longer  follow  up  (median  6.6 
years), there were 407 Gleason 8-10  patients,  almost 
half (45%) received adjuvant treatment and 25% were 
LN +. The overall 10 year progression free survival 
was 36% and cause specific survival was 85%. For the 
patients  not  selected  for  adjuvant  treatment,  the  10 
y e a r   p r o g r e s s i o n   f r e e   s u r v i v a l   w a s   2 3 % ,   c o m p a r e d   t o  
53% for those that received additional treatment. 
From the above studies, it is evident that other 
factors such as pre treatment PSA and the pathologi-
cal findings have an influence o n   o u t c o m e   f o r   t h e   h i g h  
g r a d e   c a n c e r s .   I n   a   s t u d y   ( 2 8 )   o f   1 8 8   G l e a s o n   8 -10 pa-
t i e n t s   t h e   5   y r   d i s e a s e   f r e e   s u r v i v a l   w a s   7 1 %   ( d r o p-
p i n g   t o   5 6 %   a t   7   y e a r s ) .   F o r   p a t i e n t s   w i t h   e x t e n s i o n  
outside the gland (pT3a) if margins were negative, 5 
y r   D F S   w a s   8 4 %   v e r s u s   62% if margins were positive. 
T h e   s a m e   e f f e c t s   o f   m a r g i n   s t a t u s   w e r e   s e e n   i n   a  
composite study (30) of 3 institutions with 318 Glea-
son 8-1 0   p a t i e n t s .   T h o s e   w i t h   p o s i t i v e   m a r g i n s   h a d   a  
1 7 %   7   y e a r   d i s e a s e   f r e e   s u r v i v a l   c o m p a r e d   t o   4 5 %   f o r  
those  with  negative m a r g i n s .   T h i s   w a s   a t   a   m o d e s t  
m e d i a n   3 8   m o n t h s   o f   f o l l o w   u p ,   b u t   h i g h   g r a d e   i s   s o  
highly predictive of failure, even in a study (47) with 
s h o r t   f o l l o w   u p   ( m e d i a n   2 1   m o n t h s ) ,   5 1 %   o f   G l e a s o n  
8-10 patients had already failed, resulting in a 5 year 
PSA failure free survival of 40%. Patients with organ 
c o n f i n e d   d i s e a s e   d i d   b e t t e r   ( 7 3 %   5   y e a r   d i s e a s e   f r e e  
survival) than those with EPE (40%) or SV+ (30%). 
Pretreatment  PSA  also  modified  the  outcome  in 
Gleason 8-10 patients. In a study (48) utilizing biopsy 
grade, the most favorable subgroup was Gleason 8-10 
p a t i e n t s   w i t h   a   P S A   < 1 0 ,   w h o   h a d   a   4 7 %   5   y e a r   d i s-
e a s e   f r e e   s u r v i v a l ,   w h i c h   d r o p p e d   t o   1 9 %   i f   t h e   P S A  
w a s   >   1 0   n g / m l .   I n   a   b r o a d e r   c o n t e x t ,   f o r   P S A   <   2 0  
n g / m l ,   5   y r   d i s e a s e   f r e e   s u r v i v a l   w a s   3 8 %   a n d   i f   t h e  
PSA  was   > 2 0   n g / m l ,   a l l   t h e   p a t i e n t s   h a d   f a i l e d .   F o r  
lower  grade  cancers  (Gleason  <8),  PSA  still  had  a 
s t r o n g   i n f l u e n c e   w i t h   a   5   y e a r   d i s e a s e   f r e e   s u r v i v a l   o f  
5 5 %   f o r   P S A   <   1 0   n g / m l ,   b u t   d r o p p i n g   t o   4 5 %   i f   P S A  
u p   t o   2 0   n g / m l   w a s   i n c l u d e d .   I n   a n o t h e r   s t u d y   ( 3 8 ) ,  
th e   2 4   m o n t h   d i s e a s e   f r e e   s u r v i v a l   f o r   G l e a s o n   8 -10 
w i t h   P S A   < 1 0   n g / m l   w a s   o n l y   5 9 % ,   d r o p p i n g   t o   2 5 %  
i f   t h e   P S A   w a s   > 1 0   n g / m l .   F o r   o r g a n   c o n f i n e d   p a-
tients with Gleason 8-10 cancer, the 34 month disease 
free survival was only 71%. I f   t h e r e   w a s   E P E ,   i t   w a s  
50% ,   w h i c h   w a s   n o t   m u c h   d i f f e r e n t   t h a n   m a r g i n   p o s-
itive at 54%. 
As  discussed  earlier,  some  studies  find  that 
Gleason  7  patients  have  outcomes  comparable  to 
Gleason  8-10 and therefore report them together. In 
106  Gleason  7-1 0   p a t i e n t s   w i t h   l o n g   t e r m   f o l l o w   u p  
(median  7  years),  38%  received  adjuvant  radiation 
(41). For the non organ confined patients, only 34% 
w e r e   f r e e   o f   P S A   f a i l u r e   a n d   a t   1 0   y e a r s ,   o n l y   2 2 % .   B y  
1 0   y e a r s ,   2 2 %   h a d   d i e d   o f   c a n c e r .   I n   a n o t h e r   s t u d y   ( 4 9 )  
evaluating Gleason 7-10 patients, the 5 year   P S A   r e-
currence free survival was 42%. For patients with PSA 
> 2 0   n g / m l   o r   G l e a s o n   > 7 ,   t h e   m a r g i n   n e g a t i v e   5   y e a r  
biochemical failure free survival was 60%, but with 
margin positive, it dropped to 15%.  
Some studies have found that Gleason 4+3 pa-
tients do w o r s e   t h a n   G l e a s o n   3 + 4   p a t i e n t s ,   w i t h   o u t-
c o m e s   s i m i l a r   t o   G l e a s o n   8   p a t i e n t s .   I n   o n e   s t u d y ,   ( 5 0 )  
the 354 Gleason 3+4 patients had a 72% 5 year recur-
rence  free  survival  (PSA  >0.4  ng/ml)  compared  to 
62% for the 178 Gleason 4+3 patients. This was not 
significa n t   o n   m u l t i v a r i a t e   a n a l y s i s .   I n   a   s t u d y   c o n s i-
dering EPE and margin status (51) for 97 Gleason 4+3 
patients  with  extensive  extraprostatic  extension  and 
negative margins or Gleason 3+4 with positive mar-
g i n s ,   t h e   5   y e a r   d i s e a s e   f r e e   s u r v i v a l   w a s   5 5 %   a n d   1 0  
year was 31%. For the 18 Gleason 4+3 patients with 
extensive extraprostatic extension and positive mar-
gins, it was 39% and 16%, respectively. Other studies 
(35, 52) also show that primary grade 4 cancers were 
more likely to fail than grade 3 on univariate analysis, 
but  not  on  multivariate  analysis  when  considering 
such factors as seminal vesicle and lymph node in-
volvement. 
In  summary,  as  with  seminal  vesicle  involve-
ment,  Gleason  8-1 0   c a n c e r   i s   a   c o n s i s t e n t l y   s t r o n g  
p r e d i c t o r   o f   f a i l u r e .   I n   m i g h t   b e   p o s s i b l e   to identify 
p a t i e n t s   w i t h   o r g a n   c o n f i n e d   d i s e a s e   o r   l o w   p r e o p e r-
ative  PSA  that  might  do  well,  but  in  most  studies, 
these are very small subgroups and hence the data is 
tenuous. In a preoperative clinical trial, anyone with a 
biopsy Gleason of 8-10 was deemed   a t   e n o u g h   r i s k   t o  
warrant neo adjuvant chemo and hormonal therapy 
(18). The body of data indicates that Gleason 8-10 pa-
t i e n t s   h a v e   a   h i g h   e n o u g h   r i s k   o f   f a i l u r e   t o   w a r r a n t  
immediate adjuvant treatment.  
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Table 2: Effect of high grade (Gleason 8-10) on recurrence post prostatectomy 
Gl 8-10                 
Study  # pts  PSA 
Failure 
Months 
Med f/u 
(mean) 
modifiers  Failure rate  5 yr DFS  7 yr DFS  10 yr DFS 
Han21   2091  > 0.2  71  PSA 0-4   
NS  ECE+    44%    21% 
ECE-    78%    63% 
PSA 4-10   
ECE+    37%    15% 
EPE-    75%    57% 
PSA 10.1-20   
EPE+    31%    11% 
EPE-    71%    52% 
PSA>20   
EPE+    25%    7% 
EPE-    66%    -- 
Han22  160  >0.2  (76)      44%  29%  15% 
Roehl24  237  > 0.3  (65)          32% 
Mian28  188  > 0.1  60      71%  56%   
50      EPE+mar-    84%     
16      EPE+mar+    62%     
Stephenson30   118  > 0.2 x2  38  Mar+      17%   
200  Mar-      45%   
Hull 32  38  0.4  47      49%    41% 
Frazier 43  51  >0.5  NS    69%       
 Epstein 44  41  >0.2  72(78)      59%*    35% 
Ohori45  268#  >0.4  30      55%     
Rodriquez47   180  > 0.2  21    51%  40%     
Grossfeld 48  77  > 0.2x2  37  PSA<10    47%    -- 
37  PSA>10    19%    -- 
DFS= disease free survival based on PSA 
Mar+ is margin positive; Mar- is margin negative; EPE+ is extraprostatic extension present; EPE- is extraprostatic extension absent; foc is 
focal; Ext is extensive; Est is established; Gl is Gleason score. #Gleason 7-10; * 4 years 
 
Table 3: effect of preoperative PSA on failure 
PSA                 
Study  # pts  PSA 
Failure 
Months 
Med f/u 
(mean) 
modifiers  Failure rate  5 yr DFS  7 yr DFS  10 yr DFS 
Han22  351  >0.2  (76)  10.1-20    73%  57%  54% 
100  >20  60%  48%  48% 
Hull 32  164  0.4  47  10-19.9    69%    69% 
68  50%    46% 
Stamey55   114  > 0.07  64 (67)  >10  67%  --  --  -- 
57  >15  84%  --  --  -- 
30  >20  93%  --  --  -- 
Gonzalez59   115  >0.2  67  >20  52%  --  --  -- 
DFS= disease free survival based on PSA 
 
Prostate Specific Antigen 
P S A   h a s   l o n g   b e e n   r e c o g n i z e d   a s   a   p r e d i c t o r   o f  
failure. Patients with PSA levels in the hundreds and 
thousands almost always have metastatic disease and 
if not at presentation, will in short order. In general, 
the chances of developing systemic disease decreases 
the lower the PSA. Historically, one of the statistical 
dividing lines for risk is a PSA of about 20 ng/ml. 
While patients with levels a b o v e   t h a t   f r e q u e n t l y   s u f f e r  
P S A   r e c u r r e n c e   a f t e r   t r e a t m e n t ,   i t   i s   n o t   a l w a y s   e v i-
d e n t   t h a t   r e c u r r e n c e   i s   s y s t e m i c .   F r o m   a   p r a c t i c a l  
standpoint, currently there are very few patients that 
p r e s e n t   w i t h   a   P S A   a b o v e   2 0   n g / m l   a n d   e v e n   f e w e r  
that undergo surgery .   A s   a   r e s u l t ,   n o t   t o o   m a n y   s t u-
dies report on PSA as a stand alone factor and as evi-
denced by our discussion so far, is often considered in 
r e f i n i n g   t h e   m e a n i n g   o f   o t h e r   r i s k   f a c t o r s .   I n   f a c t ,   i t   i s  
n o t   u n c o m m o n   w h e n   m u l t i p l e   f a c t o r s   a r e   e v a l u a t e d  
(especia l l y   r e g a r d i n g   d e t a i l s   o f   p a t h o l o g y   s u c h   a s  
l y m p h   n o d e ,   s e m i n a l   v e s i c l e ,   o r   m a r g i n   s t a t u s )   t h a t  Journal of Cancer 2011, 2 
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P S A   i s   n o   l o n g e r   a   s i g n i f i c a n t   f a c t o r   o n   m u l t i v a r i a t e  
analysis (52,53) . 
In a study done of patients from early in the PSA 
era (55), for patients with peripheral zone cancer and 
a   P S A   > 1 0   n g / m l ,   o n l y   3 3 %   w e r e   c u r e d .   I f   t h e   P S A  
w a s   g r e a t e r   t h a n   1 5   n g / m l ,   t h e   c u r e   r a t e   d r o p p e d   t o  
16% and for PSA >20 ng/ml, 7%. In a study (26) that 
also included adjuvant treatment, with a mean follow 
u p   o f   5 . 6   y e a r s ,   i n   p a t i e n t s   w i t h   a   P S A > 2 0   n g / m l ,   t h e  
5 year biochemical recurrence free survival was 58%. 
I n   a   l a r g e   c o h o r t   ( 2 3 )   w i t h   c o m p a r a b l e   f o l l o w   u p  
(mean 6.3 years), for patients with PSA 10.1-20 ng/ml, 
5 year disease free survival was 73% and 10 year was 
5 7 % .   F o r   P S A   > 2 0   n g / m l, it was 60% and 48%, re-
spectively. Finally, i n   a   s t u d y   ( 3 2 )   w i t h   s l i g h t l y   s h o r t e r  
f o l l o w   u p   ( m e d i a n   4 7   m o n t h s ) ,   f o r   p a t i e n t s   w i t h   a  
PSA of 20-49 ng/ml, the 5 and 10 year recurrence free 
survival rates were 50% and 46%,  respectively.  For 
those with a PSA of 10-19.9 ng/ml, the 5 and 10 year 
rates were both 69%. 
S o m e   ( 5 6 )   h a v e   f o u n d   t h a t   a   h i g h   p r e o p e r a t i v e  
P S A   v e l o c i t y   w a s   p r e d i c t i v e   o f   i n c r e a s e d   r i s k   o f   c a n-
cer death, although the inclusion of lymph node posi-
tive patients skewed the results negatively; patients 
w i t h   t h e   e l e v a t e d   P S A   v e l o c i t y   h a d   a   4 8 %   f a i l u r e   r a t e ,  
which  was  similar  to  Gleason  8-10  patients  (54%). 
Unfortunately, as this study demonstrated, many pa-
t i e n t s   d o   n o t   h a v e   e n o u g h   p r e o p e r a t i v e   P S A s   t o   d e-
termine  velocity.  In  addition,  not  all  studies  have 
found  that  preoperative  PSA  velocity  or  doubling 
time predicts for recurrence (57,58). The high number 
o f   p a t i e n t s   t h a t   d o   n o t   h a v e   t h i s   i n f o r m a t i o n   a v a i l a b l e  
makes  the  conclusions  uncertain,  and  hampers  it 
w i d e s p r e a d   a d o p t i o n .   I t   i s   a n o t h e r   o n e   o f   t h ose factors 
that if available would help support proceeding with 
treatment in an uncertain situation.  
I n   s h o r t ,   i t   i s   u n l i k e l y   t o   h a v e   p a t i e n t s   w i t h   a n  
elevated PSA without other high risk findings and it 
will  serve  as  confirmation  that  adjuvant  treatment 
m i g h t   b e   i n d i c a t e d .   A s   a   s t a n d   a l o n e   f a c t o r ,   c e r t a i n l y   i t  
indicates enough risk to warrant adjuvant treatment. 
T h e   e x a c t   p a t t e r n   o f   f a i l u r e   i n   t h e s e   p a t i e n t s   h a s   n o t  
been  well  studied  and  some  of  them  might  benefit 
from local instead of defaulting to systemic adjuvant 
treatment.  Given  the  paucity  of  patients,  it  will  be 
difficult to refine this in the future. 
Extraprostatic extension and positive margins 
Conceptually,  as  with  most  cancers,  men  that 
have  cancer  extending  outside  of  the  gland  and/or 
positive margins are at a high risk of recurrence. Early 
i t   o n ,   i t   w a s   t h o u g h t   t h a t   t h o s e   p a t i e n t s   h a d   s u c h   a  
h i g h   r i s k   o f   r e c u r r e n c e   t h a t   t h e y   w e r e   “ n o t   c u r a b l e   b y  
surgery alone”. (60) As our experience with prostate 
c a n c e r   h a s   e v o l v e d   t o   w h e r e   i t   i s   n o t   a s   a d v a n ced at 
p r e s e n t a t i o n ,   t h e   p r o g n o s i s   h a s   i m p r o v e d ,   b u t   t h o s e  
factors do still offer some prediction as to recurrence. 
Both extraprostatic extension (EPE) and margin 
status  offer  prognostic  information.  Various  studies 
f i n d   t h a t   o n e   m a y   b e   m o r e   d o m i n a n t   t h a n   the other, 
b u t   i n   m o s t   c a s e s ,   i t   i s   r e a l l y   h a r d   t o   s e p a r a t e   t h e   t w o .  
The  likelihood  of  being  significant  on  multivariate 
a n a l y s i s   d e p e n d s   o n   t h e   m u l t i p l e   o t h e r   f a c t o r s   w i t h  
w h i c h   t h e y   a r e   e v a l u a t e d .   ( 2 1 , 3 3 )   F o r   e x a m p l e ,   i f   S V  
positive or LN positive patients are included, margin 
s t a t u s   o r   E P E   m a y   n o t   b e   i n d e p e n d e n t l y   p r e d i c t i v e  
d u e   t o   t h e   o v e r w h e l m i n g   r i s k   o f   f a i l u r e   a s s o c i a t e d  
with those two factors. Although at times they are the 
most  predictive  factor,  as  a  stand  alone  factor,  they 
usually don’t have the overwhelming failure risk as-
sociated with SV positive, LN positive and high grade 
cancers. With that, it is the additional risk they convey 
i n   a d d i t i o n   t o   o t h e r   f a c t o r s   t h a t   m a k e   t h e m   s o   i m p o r-
tant. 
T h e   f i r s t   r e a l   c h a l l e n g e   i s   a s   t o   h o w   t o   d e f i n e   e x-
traprostatic  extension  and  margin  positivity.  EPE  is 
often used interchangeably with extracapsular exten-
s i o n .   S i n c e   t h e   p r o s t a t e   d o e s   n o t   h a v e   a   c o m p l e t e  
c a p s u l e ,   i t   c a n   b e   a r g u e d   t h a t   E P E   i s   a   m o r e   a c c u r a t e  
d e s c r i p t i o n .   I n   s i m p l e   t e r m s ,   i t   m e a n s   c a n c e r   e x t e n d-
ing outside the prostate proper. That is relatively easy 
if there is attached fat, but if the prostate edge is bare, 
t h e n   i t   i s   m o r e   s u b j e c t i v e .   T h e   s a m e   i s   t r u e   w i t h   p o s i-
t i v e   m a r g i n s .   I t   i s   a   r e l a t i v e l y   e a s y   c a l l   i f   t h e r e   i s   c a n-
c e r   o u t   i n t o   f a t   a n d   i t   i s   p r e sent at the inked cut edge. 
I t   i s   a   l i t t l e   m o r e   p r o b l e m a t i c   i f   t h e r e   i s   n o   c a p s u l e   o r  
fat and then it simply means that there is cancer at the 
i n k e d   e d g e .   T h i s   i s   h o w   a n   o r g a n   c o n f i n e d   c a n c e r   c a n  
h a v e   a   p o s i t i v e   m a r g i n ;   t h e   c a n c e r   i s   t o   t h e   s u r f a c e   o f  
the b a r e   g l a n d   a n d   i s   i n   c o n t a c t   w i t h   i n k .   O f   c o u r s e ,  
t h e   a b i l i t y   t o   d e t e c t   E P E   a n d   p o s i t i v e   m a r g i n s   d e-
p e n d s   o n   h o w   d i l i g e n t l y   i t   i s   s o u g h t .   T h e   m o s t   c o m-
plete routine is probably whole mount with uniform 
step sectioning and then diligent analysis of each and 
every slide. This is extremely time consuming, so in 
m o s t   i n s t a n c e s   t h i s   d e g r e e   o f   s c r u t i n y   i s   r a r e l y   r o u-
t i n e l y   u n d e r t a k e n .   S u f f i c e   i t   t o   s a y ,   t h e   i s s u e   o f   E P E  
a n d   m a r g i n   s t a t u s   i s   s o m e w h a t   s u b j e c t i v e ,   s o   c a u t i o n  
should be made in not over interpreting their signi-
ficance, especially as an isolated finding. The defini-
t i o n   a n d   t h e   p a t h o l o g i c a l   d e t e r m i n a t i o n   o f   c a p s u l a r  
penetration,  extra  capsular  or  prostatic  extension, 
capsular incision and positive margins is not uniform 
and  not  straightforward  (61),  which  probably  ac-
c o u n t s   f o r   s o m e   o f   t h e   v a r i a b i l i t y   a s   t o   h o w   t h e s e  
factors impact on prognosis. 
In an early radical retropubic cohort (1969-1993) 
(62) w i t h   a   m i n i m u m   o f   1 0   y e a r s   o f   f o l l o w   u p ,   t h e   1 0  Journal of Cancer 2011, 2 
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year clinical progression and/or PSA failure free sur-
vival  was  6 3 % .   F o r   p a t i e n t s   w i t h   n o   c a p s u l a r   i n-
volvement it was 69%, for the 24 with invasion into, 
but not through, it was similar at 67%, while for the 26 
men with invasion through the capsule, it dropped to 
39%.  In  another  long  term  study  (23)  patients  with 
EPE had a 39% failure rate and 11% death rate by 12 
years. 
M a r g i n   s t a t u s   h a s   a l s o   b e e n   f o u n d   t o   b e   a n   i n-
dependent predictor of recurrence. In an early study 
in  perineal  prostatectomy  patients  (63),  for  patients 
with positive margins, 5 year biochemical recurrence 
was 58%, which resulted in a cancer death rate of 40% 
at  13.5  years.  Patients  with  positive  margins  had 
d o u b l e   t h e   o v e r a l l   d e a t h   r a t e   ( 6 0 % )   a s   t h o s e   w i t h   o r-
gan or specimen confined disease (30%).  
M u l t i p l e   o t h e r   s t u d i e s   ( T a b l e   4 )   h a v e   s h o w n   t h a t  
margin  positive disease has a 19-64% (64-70)  recur-
rence rate for a 5 year failure free survival of 37%-86% 
(26,30,44,65,69-71) and 10 year failure free survival of 
26%-61%(31,44,64).  If  patients  have  other  high  risk 
f a c t o r s   ( i . e .   P S A   > 2 0   n g / m l   a n d   G l e a s o n   > 7 )   t h e  5   y e a r  
r e c u r r e n c e   f r e e   s u r v i v a l   i s   v e r y   l o w   ( 1 5 % ) ( 4 9 )   S t i l l ,  
s o m e   s t u d i e s   h a v e   f o u n d   m a r g i n   s t a t u s   t o   b e   i r r e l e-
v a n t .   I n   t h e   f i r s t   o f   t w o   s t u d i e s   b y   t h e   s a m e   a u t h o r  
(35) (mean follow up of 41 months) on multivariate 
analysis, LN positive, pathologic stage (i.e. EPE), se-
minal vesicle involvement and Gleason score were all 
p r o g n o s t i c   a t   t h e   e x c l u s i o n   o f   m a r g i n s   o r   c a p s u l a r  
i n v a s i o n .   I n   t h e   l a t e r   s t u d y   ( 7 2 ) ,   ( m e a n   f o l l o w   u p   5 5  
m o n t h s ) ,   P S A   w a s   t h e   o n l y   s i g n i f i c a n t   f a c t o r   o n   m u l-
tivariate analysis.  
The finding of EPE has some prognostic power 
i n d e p e n d e n t   o f   m a r g i n   s t a t u s .   F o r   E P E   p o s i t i v e   d i s-
ease,  5  year  failure  free  survival  is 
48%-68%(26,71).More  specifically,  for  EPE  positive 
margin negative disease, 5 year failure free survival is 
48%-76%(24,32,64) and 10 year failure free survival is 
46-9 0 % .   I n   p a t i e n t s   w i t h   b o t h   E P E   a n d   m a r g i n   p o s i-
t i v e   d i s e a s e ,   5   y e a r   f a i l u r e   f r e e   s u r v i v a l   i s   3 3 -55% 
(24,31,32,64,65,66,73) and 10 year failure free survival 
is 20%-53%.  
In  most  studies,  while  both  margin  positivity 
and EPE are each predictive, the two together yield a 
worse prognosis. In a study that excluded LN positive 
p a t i e n t s   ( 1 6 ) ,   w i t h   a   m e d i a n   f o l l o w   u p   o f   1 2 1   m o n t h s ,  
3 7 %   p a t i e n t s   r e c u r r e d .   F o r   o r g a n   c o n f i n e d   p a t i e n t s ,  
25%  recurred,  which  increased  to  44%  for  EPE  but 
margin  negative  patients  and  64%  with  EPE  and 
margin positive patients. Ten year disease free sur-
v i v a l   w a s   5 6 %   f o r   E P E   p o s i t i v e   m a r g i n   n e g a t i v e   a n d  
3 2 %   f o r   E P E   p o s i t i v e   a n d   m a r g i n   p o s i t i v e   p a t i e n t s ,  
respectively. In another study (74) the margin nega-
tive  patie n t s   h a d   a   c l i n i c a l   r e c u r r e n c e   r a t e   o f   1 3 %  
versus 39% for margin positive. For 5 year PSA pro-
g r e s s i o n   ( P S A   > 1 . 0   n g / m l ) ,   p a t i e n t s   w i t h   p a t h o l o g i c a l  
e x t e n s i o n   o u t s i d e   t h e   g l a n d   ( p T 3 -4)  with  margins 
positive had a 52% (from the graph) progression rate, 
but was   o n l y   2 5 %   i f   t h e   m a r g i n s   w e r e   n e g a t i v e   ( E P E  
p o s i t i v e ,   m a r g i n   n e g a t i v e ) .   I n   a n   u p d a t e d   s t u d y   f o r  
patients with pathologically locally extensive disease 
( p T 3 ;   E P E   p o s i t i v e ) ,   t h e   5   a n d   1 0   y e a r   c l i n i c a l   p r o-
gression was 34% and 75%, respectively.  
F r o m   t h e   p r e c e d i n g ,   i t   a p p e a r s   t h a t   b o t h   E P E   a n d  
margin involvement have a negative effect on recur-
r e n c e ,   a l t h o u g h   m a y b e   n o t   i n   a l l   c a s e s   t o   t h e   s a m e  
independent  degree  as  the  factors  we  have  already 
reviewed (high PSA, Gleason 8-10 cancer and/or se-
minal vesicle involvement). 
 For  patients  with  intermediate  findings  (i.e. 
Gleason  <  7 ) ,   t h e   a d d i t i o n   o f   E P E   a n d / o r   p o s i t i v e  
m a r g i n s   m a y   p r e s e n t   e n o u g h   r i s k   t o   w a r r a n t   i m m e-
diate  adjuvant  treatment.  For  example,  in  a  large 
study (23) with a mean follow up of 6.3 years, patients 
with <Gleason 7 cancer and extraprostatic extension 
w i t h   n e g a t i v e   m a r g i n s   d i d   j u s t   a s   w e l l   a s   p a t i e n t s   w i t h  
o r g a n   c o n f i n e d   d i s e a s e ,   w i t h   a   1 5   y e a r   r e c u r r e n c e   f r e e  
s u r v i v a l   o f   8 4 % .   I f   t h e   m a r g i n s   w e r e   p o s i t i v e ,   i t   w a s  
only  58%. I n   a n o t h e r   l a r g e   s t u d y   ( 2 4 ),  patients  with 
organ confined disease did moderately well even if 
t h e y   h a d   a   h i g h   g r a d e   c a n c e r   a n d / o r   P S A   > 1 0   n g / m l  
w i t h   a   7   y e a r   d i s e a s e   f r e e   s u r v i v a l   r a t e   o f   5 9 % .   F o r  
p a t i e n t s   w i t h   E P E   a n d   P S A > 1 0   n g / m l ,   e v e n   i f   t h e y  
had a  well  differentiated cancer,  the  7  year  disease 
free survival dropped dramatically to 25%. For mod-
erately  differentiated  cancers  (i.e.  Gleason  7)  with 
E P E ,   f o r   P S A   <   1 0   n g / m l ,   t h e   7   y e a r   d i s e a s e   f r e e   s u r-
vival was 46%, but only 11% with PSA > 10 ng/ml. Of 
course, the patients with poorly differentiated tumors 
and  EPE  did  poorly;  with  PSA  <  10  ng/ml  46%  and 
P S A   >   1 0   n g / m l   5 %   7   y e a r   d i s e a s e   f r e e   s u r v i v a l .  In 
a n o t h e r   s t u d y   f o r   t h e   2 6 4   p o s i t i v e   m a r g i n   p a t i e n t s  
(75), the overall 5 year failure free survival was 80%. 
The intermediate risk patien t s   ( P S A   1 0 -2 0   n g / m l   o r  
Gleason 7 disease) initially did fairly well with a 5 
y e a r   d i s e a s e   f r e e   s u r v i v a l   o f   7 8 % ,   b u t   i t   d r o p p e d   p r e-
cipitously to 23% at 10 years. The high risk (PSA >20 
n g / m l   o r   G l e a s o n   8 -10) patients had 100% failure by 
10 years. 
I n   a   m o r e  aggressive approach, one study of (34) 
862 patients looked specifically at the 2 year failure 
rate, with the supposition that those patients would 
be  more  likely  to  develop  metastatic  disease.  With 
t h a t ,   t h e y   p r o p o s e d   t h a t   a   2   y e a r   f a i l u r e   r a t e   o f   > 5 0 %  
was certainly enough to warrant adjuvant interven-
t i o n .   P a t i e n t s   w i t h   E P E   a n d   G l e a s o n   7 -10 cancers had 
a   u n i f o r m l y   h i g h   r i s k   o f   2   y e a r   f a i l u r e .   F o r   m a r g i n  
negative patients some of the Gleason 7 patients with Journal of Cancer 2011, 2 
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l o w   P S A   l e v e l s   h a d   a   r e l a t i v e l y   m o r e   m o d e s t   r i s k   o f 
failure. For example, in Gleason 7, margin negative, 
PSA 0-4   n g / m l   p a t i e n t s ,   t h e   2   y e a r   r i s k   o f   f a i l u r e   w a s  
1 8 % .   A l t h o u g h   i t   c a n   b e   a r g u e d   t h a t   i s   a   f a i r l y   b r i s k  
f a i l u r e   r a t e   f o r   j u s t   2   y e a r s ,   i t   d o e s   i n d i c a t e   t h a t   s o m e  
of  those  patients  will  do  well.  As discussed  earlier, 
c a u t i o n   m u s t   b e   e x e r c i s e d   i n   t a k i n g   t h e s e   r e s u l t s   t o o  
literally due to small numbers. This study does raise 
another potential prognostic factor in that for patients 
with  EPE,  there  was  a  difference  between  patients 
with  established  (extensive)  margin  involvement 
versus focal, with the latter patients having an aver-
age of 28% (18-33%) less risk of failure across all the 
PSA levels and Gleason scores. 
T h i s   c o n f i r m s   s o m e   o f   t h e   e a r l i e r   w o r k   b y   t h i s  
group (73). In known high risk patients (Gleason 8-10, 
L N   p o s i t i v e ,   S V   p o s i t i v e )   t h o s e   r e c e i v i n g   a d j u v a n t  
treatment were excluded. For patients with Focal EPE 
and margins negative disease, 5 year PSA recurrence 
f r e e   s u r v i v a l   w a s   6 9 % ,   d r o p p i n g   t o   4 5 %   i f   t h e r e   w a s  
extensive EPE. In another example (76) for Gleason 7 
patients  with  organ  confined  disease  and  negative 
margins, 5 and 10 year progression free survival were 
97% and 68%, which dropped to 83% and 48% with 
Gleason 7 patients with focal extraprostatic extension 
positive (with or without positiv e   m a r g i n s )   o r   e s t a b-
lished extraprostatic extension and negative margins. 
For  patients  with  Gleason  7  and  established  extra-
p r o s t a t i c   e x t e n s i o n   a n d   p o s i t i v e   m a r g i n s ,   t h e   5   y e a r  
progression free survival was 50% and 10 year was 
42%.  
Several other studies have shown similar results. 
For example, (66,77) patients with multiple margins 
h a d   a   h i g h e r   r i s k   o f   f a i l u r e   ( 4 4 % , 2 7 % )   t h a n   t h o s e   w i t h  
a   s i n g l e   m a r g i n   ( 2 1 % , 1 5 % ) .   O t h e r   s t u d i e s   h a v e   r e-
ported similar findings (30,53,67), although it is not 
always an independent predictive factor on multiva-
riate analysis. (78)  
I t   i s   c l e a r   ( T a b l e   4 )   t h a t   E P E   a n d   m a r g i n   s t a t u s  
have an effect on failure, especially when considered 
t o g e t h e r .   I t   c a n   b e   a r g u e d   t h a t   t h e   f a i l u r e   r i s k   a p-
p r o a c h e s   t h o s e   o f   h i g h   G l e a s o n   s c o r e   a n d   S V   i n-
volvement patients, but there are patients with those 
f a c t o r s   t h a t   m a y   n o t   h a v e   t h a t   h i g h   o f   a   r i s k   a n d   t h e  
assessment is much more complicated. It would ap-
pear  that  patients  with  Gleason  7  cancer  and  the 
combination of EPE and positive margins have a high 
enough risk that they should be uniformly considered 
for adjuvant treatment.  
 
Table 4: effect of extraprostatic extension and positive margins on failure 
Study  # pts  PSA 
Failure 
monthsMed 
f/u (mean) 
Modifiers  Failure rate  5 yr 
DFS 
7 yr 
DFS 
10 yr 
DFS 
15 yr 
dfs 
Swanson16  39  >0.3  121  EPE+mar-  44%  66%    56%   
105  EPE+mar+  64%  52%    32%   
Han 22  135  >0.2  (76)  EPE+ Gl>6 mar +    58%  42%  42%  33% 
326  EPE+ Gl>6 mar -    80%    61%  59% 
Roehl 24  632  > 0.3  (65)  EPE+mar+        53%   
255  EPE+mar-        62%   
Stephenson 30  1501  > 0.2 x2  38  Mar +      60%     
5659  Mar -      88%     
501  EPE+Mar +      52%     
928  EPE+Mar -      74%     
Karakiewiz31  1083  0.1-0.4  25  EPE+mar-    66%    46%   
613  EPE-mar+    74%    61%   
941  ECE+Mar+    43%    25%   
Hull 32  251  0.4  47  EPE+mar-    76%    71%   
126  mar+    42%    36%   
Kupelian49  195  >0.2  41  Mar+    36%       
Paulson 63  225  >0.4  NS  Mar +    58%       
Pfitzenmaier64  60  > 0.2  62  Mar+  64%  38%    26%   
--  ECE+mar+    33%    20%   
--  ECE+mar-    62%    46%   
Cheng 65  109  >0.2  (70)  Mar +    70%       
72  Mar+ EPE-    78%       
37  Mar+ EPE+    55%       
Simon 66  350  >0.3  (46)  Mar+  19%         
586  Mar-  7%         
268  EPE+  29%         
87  Mar+EPE+  39%         
153  Mar+ Gl7  20%         
50  Mar+Gl8-10  52%         
121  Mar+ PSA10-20  31%         Journal of Cancer 2011, 2 
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47  Mar+ PSA>20  64%         
Pettus 67  28  0.2 x 2  53 (55)  Apical +  21%  79%    79%   
57  Focal +  26%  84%    74%   
13  Multi +  31%  69%    69%   
Vis 68  66  > 0.1  81  Mar+  33%         
Mann 70  128  >0.1  68  Mar+    86%  75%     
387  Mar-    95%  88%     
194  54  Mar +    84%  56%     
633  Mar-    95%  82%     
Kupelian71  144  >0.2  36  Mar+    37%       
206      EPE+    48%       
D’Amico 72  57  > 
undetectable 
57  Gl 
2-7 
Foc EPE+ mar-    69%       
22  Ext EPE+ mar-    45%       
118  EPE+ Mar+    33%       
Alkhateeb75  264  > 0.4  79  Mar+    74%    50%   
*all patients failure defined at 2 years Mar+ is margin positive; Mar- is margin negative; EPE+ is extraprostatic extension present; EPE- is 
extraprostatic extension absent; foc is focal; Ext is extensive; Est is established; Gl is Gleason score 
 
Modifying factors 
In trying to predict risk of recurrence after radi-
cal prostatectomy, numerous other potential modify-
ing  risk  factors  that  have  been  evaluated.  Unfortu-
n a t e l y ,   e v e n   i f   t h e y   w e r e   s h o w n   t o   b e   p o s i t i v e   o n  
multivariate analysis, they are rarely evaluated as to 
h o w   t h e y   m o d i f y   o r   i m p r o v e   t h e   s t a n d a r d   f a c t o r s ,   s o  
their utility remains questionable. Certainly they have 
n o t   b e e n   p r o v e n   t o   b e   p o w e r f u l   e n o u g h   a   p r e d i c t o r   t o  
b e   u n i f o r m l y   a d o p t e d .   I t   i s   n o t   u n r e a s o n a b l e   t o   con-
s i d e r   t h e s e   f a c t o r s   i n   p a t i e n t s   w h o   o t h e r w i s e   h a v e  
borderline risk where the presence of absence of these 
factors might aid in the final decision-making.  
O n e   o f   t h e   f a c t o r s   t h a t   h a s   b e e n   e v a l u a t e d   i s   t h a t  
o f   a g e .   I t   d o e s n ’ t   t a k e   a   s t u d y   t o   t e l l   u s   t h a t  age will 
h a v e   a n   e f f e c t   o n   o v e r a l l   s u r v i v a l ,   b u t   i t   i s   w o r t h  
a s k i n g   i f   y o u n g e r   o r   o l d e r   p a t i e n t s   h a v e   a   h i g h e r   r i s k  
o f   c a n c e r   m o r t a l i t y .   O n e   s t u d y   ( 7 9 )   w i t h   e x t r e m e l y  
s h o r t   f o l l o w   u p   ( m e d i a n   1 9   m o n t h s ) ,   s h o w e d   o n   m u l-
tivariate analysis that men younger than 50 years of 
a g e   d i d   b e t t e r   t h a n   t h o s e   o v e r   7 0 .   T h i s   w a s   c o n f i r m e d  
b y   a n o t h e r   s t u d y   ( 8 0 )   a n d   a   t h i r d   s t u d y   ( 8 1 )   s h o w e d  
that  patients  older  than  70  had  significantly  worse 
biochemical failure free survival than those younger 
than 70. An additional study showed that patients < 
6 0   y e a r s   o f   a g e   h a d   a b o u t   1 5 %   b e t t e r   b i o c h e m i c a l  
c o n t r o l   a t   3 6   m o n t h s   t h a n   o l d e r   p a t i e n t s   ( 6 9 ) .   T h e  
benefit of younger age was confirmed on multivariate 
analysis. Finally, in (28) seminal vesicle positive pa-
t i e n t s ,   a g e   w a s   p r e d i c t i v e   o f recurrence on multiva-
r i a t e   a n a l y s i s   w i t h   o l d e r   p a t i e n t s   h a v i n g   a   s h o r t e r  
time  to  recurrence.  In  most  studies,  younger  aged 
p a t i e n t s   a r e   i n   t h e   m i n o r i t y   a n d   t h e r e   a r e   a t   l e a s t   a n  
e q u a l   n u m b e r   o f   o t h e r   s t u d i e s   t h a t   h a v e   s h o w n   a g e  
h a s   n o   i m p a c t   o n   r e c u r r e n c e. (24,53,82-84) With that, it 
appears the effect of age on recurrence is equivocal. 
S o m e   s t u d i e s   s e e m   t o   s h o w   t h a t   r a c e   h a s   a n   i m-
pact on recurrence, with black men having a higher 
recurrence rate (48,85). This has been an inconsistent 
finding  with  most  studies  not  finding  a  connec-
tion,(24,86-88) s o   a s   w i t h   a g e ,   t h e   s i g n i f i c a n c e   o f   r a c e  
remains uncertain. 
A pathologic finding that has been variable as a 
prognostic factor is that of perineural invasion (PNI). 
Ostensibly, it is a pathway that the cancer can follow 
t o   e x t e n d   o u t s i d e   o f   t h e   g l a n d .   I n   m a n y   s t u d i e s   t h a t  
r e p o r t   o n   i t ,   i t   i s   a n   o b s e r v a t i o n a l   f i n d i n g .   F o r   e x a m-
p l e ,   i n   o n e   s t u d y   ( 8 9 ) ,   o f   t h e   1 7   p a t i e n t s   t h a t   r e c u r r e d ,  
1 4   ( 8 2 % )   h a d   p e r i n e u r a l   i n v a s i o n .   O t h e r   t h a n   t h a t  
observation,  no  real  correlation  of  PNI with failure 
was possible. When considered in conjunction with 
other  factors  such  as  extraprostatic  extension  and 
positive margins, it is not independently associated 
with  recurrence.(72,90,91,98).  Although  it  sounds 
ominous,  perineural  invasion  is  not  a  strong  inde-
pendent predictor of failure. 
A n o t h e r   f a c t o r   t h a t   l o g i c   w o u l d   d i c t a t e   m a k e s  
sense as a predictor of failure is that of tumor volume. 
It would seem that the larger cancers would be harder 
to  eradicate.  As  a  stand  alone  factor,  its  predictive 
p o w e r   w o u l d   b e   s o m e w h a t   m i t i g a t e d   b y   o t h e r   p r e-
d i c t i v e   f a c t o r s ,   s u c h   a s   P S A ,   G l e a s o n   s c o r e ,   a n d   p a-
thological findings as they are often also unfavorable 
in large tumors. There are various ways of determin-
i n g   o r   e s t i m a t i n g   t u m o r   v o l u m e .   T h e   m o s t   e x a c t   o f  
which is to mount the entire specimen, carefully step 
s e c t i o n   i t   a n d   m e a s u r e   t h e   a m o u n t   o f   c a n c e r   s l i c e   b y  
s l i c e .   T h i s   i s   n o t   p r a c t i c a l   f o r   m o s t   p a t h o l o g y   d e p a r t-
m e n t s   a n d   t h e r e   a r e   u n r e s o l v e d   i s s u e s   s u c h   a s   h o w   t o  
a c c o u n t   f o r   t h e   m u l t i f o c a l i t y   o f   c a n c e r   ( i . e .  whether to 
a d d   t h e m   a l l   t o g e t h e r   v e r s u s   j u s t   a c c o u n t   f o r   t h e   d o-
m i n a n t   l e s i o n )   ( 9 2 ) .   S o m e   s t u d i e s   h a v e   f o u n d   w h a t  
appears to be an association between cancer volume 
and  outcome.  I n   a   p a p e r   o f   p e r i n e a l   p r o s t a t e c t o m y  
patients (43) tumor volume >25% was a significant 
predictor of failure on multivariate analysis. For tu-
mor volume of < 25%, the failure rate was < 25%. For Journal of Cancer 2011, 2 
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volumes  >  25%,  it  was  57-88%.  In  another  study  of 
patients from early in the PSA era (1983-1992) (55), for 
a   c a n c e r   v o l u m e   o f   2 -6   c c ,   t h e   c u r e rate (non-rising 
P S A )   w a s   5 5 % ,   f o r   6 -1 2   c c ,   2 7 %   a n d   f o r   > 1 2   c c   o n l y   3 % .  
I n   t h i s   s t u d y ,   t h e   p r i m a r y   d e t e r m i n a n t s   o f   f a i l u r e  
were Gleason pattern 4/5 and cancer volume. Unlike 
most studies, margin and SV positivity were not pre-
d i c t i v e   w h e n   v o l u m e   w a s   c o n s i dered.  Volume  can 
contribute  additional  information.  In  a  study  of  se-
minal vesicle positive patients, tumor volume actually 
added some prognostic information that were verified 
on multivariate analysis (28). It some cases, the pre-
dictive ability also holds true for relatively small tu-
m o r s   ( 2 6 ) .   P a t i e n t s   w i t h   t u m o r s   >   3 m m   h a d   a   5   y e a r  
PSA failure free survival of 68%, while for those with 
t u m o r s   <   3 m m ,   8 2 % .   C o n t r a r y   t o   t h e   a b o v e   f i n d i n g s ,  
there are several studies that have found other factors 
displace volume   a s   a   p r e d i c t i v e   f a c t o r .   ( 5 3 , 9 3 ) .   I n   o n e  
example,(94) while patients with large volume (>12 
cm3) had a much worse biochemical failure free sur-
v i v a l   a t   5   y r s   ( 3 8 % )   t h a n   s m a l l e r   v o l u m e   t u m o r s ,   i t  
was  not  significant  on  multivariate  analysis  when 
considered  with  other  factors.  Another  study  (95) 
where  the  volume  was  visually  estimated,  patients 
with <10% cancer had a 5 year disease free survival of 
94%, for 10-20% volume, 91%, and for >20% volume 
8 2 % ,   b u t   v o l u m e   w a s   n o t   p r e d i c t i v e   o n   m u l t i v a r i a t e  
analysis. 
A n o t h e r   w a y   o f   e v a l u a t i n g   c a n c e r   v o l u m e   t h a t  
eliminates having to physically determine volume is 
t h a t   o f   P S A   d e n s i t y .   T h i s   i s   d e t e r m i n e d   b y   l o o k i n g   a t  
t h e   s u r g i c a l   v o l u m e   o f   t h e   e n t i r e   g l a n d   i n   r e l a t i o n   t o  
t h e   t o t a l   P S A . ( 9 6 ) .   H i g h   r i s k   p a t i e n t s   w e r e   d e f i n e d as 
any patient with a PSA density of >0.7 or any patient 
with Gleason 8-10. The 5 year PSA failure free sur-
vival was 21%. For intermediate risk patients (density 
<0.3, Gleason 7 or Gleason 2-7 and density 0.3-0.7), it 
w a s   5 2 % .   T h e   r e s u l t s   i n   a   s e p a r a t e   g roup of patients 
w e r e   m u c h   b e t t e r   t h a n   t h i s   w i t h   a   5   y e a r   f a i l u r e   f r e e  
s u r v i v a l   o f   7 0 %   f o r   t h e   h i g h   r i s k   p a t i e n t s   a n d   7 8 %   f o r  
the intermediate risk, respectively. They did find that 
PSA  density  was  better  than  PSA  on  multivariate 
a n a l y s i s .   A s   a   f a c t o r   i n   P SA density, gland size may 
h a v e   s o m e   p r e d i c t i v e   p o w e r .   I n   o n e   s t u d y   o f   p r o s t a-
tectomy patients with extraprostatic extension and/or 
p o s i t i v e   m a r g i n s   ( 6 9 ) ,   t h o s e   w i t h   g l a n d s   <   3 0   g r a m s  
had a 10-2 0 %   h i g h e r   p r o g r e s s i o n   r a t e   t h a n   t h o s e   w i t h  
> 30 gram glands. Another study showed that a gland 
s i z e   o f   4 0   c c   g l a n d   h a d   t h e   s a m e   r i s k   o f   r e c u r r e n c e   a s  
p o s i t i v e   m a r g i n s   t h a t   d e c r e a s e d   a s   t h e   g l a n d   g o t  
larger. (97) 
As another measure of volume, there has been 
g r e a t   i n t e r e s t   i n   u s i n g   t h e   b i o p s y   c o r e s   t o   p r e d i c t  
outcome. On e   o f   t h e   b e n e f i t s   w o u l d   b e   t o   s u p p l y   s o m e  
additional prognostic information before the primary 
treatment  was  even  undertaken.  Unfortunately,  in 
s t a n d a r d   p r a c t i c e ,   a   h i g h   l e v e l   o f   d e t a i l   a b o u t   t h e   b i-
opsies is not uniformly available. For example, in the 
SEA R C H   d a t a b a s e ,   o n l y   a b o u t   h a l f   t h e   p a t i e n t s   h a d  
enough information to analyze (98). In addition, while 
the needle biopsies do predict volume, there is a wide 
variation in accuracy. (99) With these limitations, in 
the first SEARCH study, utilizing only preoperative 
p a r a m e t e r s ,   t h e   t o t a l   p e r c e n t   o f   p o s i t i v e   b i o p s y   t i s s u e  
(length  of  cancer/total  cumulative  length  of  all  the 
cores) was the strongest predictors of recurrence. (98). 
I n   a   c o n c u r r e n t   s t u d y   o f   t h e   s a m e   p a t i e n t s   ( 1 0 0 ) ,   t h a t  
wasn’t a factor, rather the core density, defined as the 
per cent of total cores positive from each side. With 
t h a t ,   h a v i n g   > 6 7 %   o f   t h e   c o r e s   f r o m   t h e   p r e d o m i n a n t  
s i d e   w a s   t h e   b i g g e s t   p r e d i c t o r   o f   f a i l u r e .   T h e s e   r e s u l t s  
w o u l d   h a v e   t o   b e   c o n s i d e r e d   p r e l i m i n a r y   a s   t h e   p r i-
mary endpoint   w a s   2   y e a r   f a i l u r e   ( w i t h   a   m e d i a n   f o l-
l o w   u p   o f   2 7   m o n t h s ) .   P a t i e n t s   w i t h   a   > 2 8 %   t w o   y e a r  
f a i l u r e   w e r e   p a t i e n t s   w i t h   > 6 7 %   c o r e s   p o s i t i v e   o n   t h e  
d o m i n a n t   s i d e   w i t h   G l e a s o n   7   a n d   P S A   > 1 0   o r   G l e a-
son 8-1 0   w i t h   a n y   P S A   o r   G l e a s o n   8 -10 with PSA >20 
and at least 3 4 %   p o s i t i v e   c o r e s .   O f   c o u r s e   t h e r e   a r e  
m u l t i p l e   d i f f e r e n t   w a y s   t o   u t i l i z e   t h e   c o r e   i n f o r m a-
tion. In another large study cited above (39), it wasn’t 
the  dominant  side  per  cent  positive  cores,  but  the 
overall number that was predictive. . Other studies 
(101)   h a v e   s h o w n   o n   m u l t i v a r i a t e   a n a l y s i s   t h a t   t h e  
percentage of positive biopsies was predictive. Still 
other studies have shown that the percentage of posi-
t i v e   c o r e s   c o u l d   m i t i g a t e   t h e   r i s k   o f   h i g h   g r a d e   c a n c e r  
( 1 0 2 ) .   F o r   e x a m p l e ,   i n   h i g h   r i s k   p a t i e n t s   ( d e f i ned  as 
P S A   > 2 0 ,   o r   G l e a s o n   8 -10  or stage  T2C/T3  disease), 
t h e   o v e r a l l   5   y e a r   r e c u r r e n c e   r a t e   a t   a   m e d i a n   o f   4 0  
months was 36%, but was 24% for 0-33% cores posi-
tive, 34% for 34-66% cores positive and 59% for >66% 
cores  positive.  This  was  significant  on  multivariate 
analysis. Another study (54) showed similar findings. 
T h e y   f o u n d   i n   a   p o s t   o p e r a t i v e   p o p u l a t i o n   t h a t   a   l o w  
n u m b e r   o f   p o s i t i v e   c o r e s   c o u l d   m i t i g a t e   t h e   r i s k   o f  
high grade. Overall the finding of >28% cores was a 
poor  prognosis,  In  Gleason  8-9 patients  with  pT2-3 
c a n c e r   a n d   m a r g i n   n e g a t i v e   w i t h   <   2 8 %   p o s i t i v e   c o r e s  
t h e r e   w a s   a n   8 5 %   5   year  progression  free  survival 
w h i c h   d r o p p e d   t o   5 4 %   w i t h   > 2 8 %   p o s i t i v e   c o r e s .   I n  
other  studies,  it’s  not  the  percentage  of  total  cores 
taken that is predictive, but the amount of any core 
t h a t   i s   i n v o l v e d .   F o r   e x a m p l e ,   i n   n o n -palpable  pros-
tate cancer (T1C)(84) that were Gleason 7-1 0   o r   P S A   >  
10 ng/ml, i f   < 5 0 %   o f   a n y   s i n g l e   c o r e   w a s   p o s i t i v e ,   t h e  
1 0   y e a r   d i s e a s e   f r e e   s u r v i v a l   w a s   8 5 % ,   c o m p a r e d   t o  
56% if >50% of any core was positive. In another, the 
t o t a l   l e n g t h   o f   h i g h   g r a d e   ( 4 / 5 )   c a n c e r   i n   t h e   b i o p s y  Journal of Cancer 2011, 2 
 
http://www.jcancer.org 
14 
cores was predictive for recurrence (68). They found 
t h a t   f o r   > 1 0 m m   o f   G l e a s o n   g r a d e   4 / 5   c a n c e r ,   r e c u r-
r e n c e   w a s   5 0 %   ( P S A   >   0 . 1   n g / m l )   a n d   f o r   3 -10 mm 
was <40%. Others (103) have  found  that  percentage 
positive cores have no predictive value. 
The problem in this and in many of the studies is 
w i t h   t h e s e   m u l t i p l e   s u b d i v i s i o n s ,   m a n y   o f   t h e   s u b-
groups are very small (< 10 patients). Also, the way of 
obtaining the cores is user dependent, with no com-
m o n   s t a n d a r d s .   G r i d s   a r e   r a r e l y   u s e d   a n d   o n e   c o u l d  
imagine how directed biopsies to the area of palpable 
tumor  rather  than  uniformly  throughout  the  gland 
could influence results. Overall, caution must be used 
to avoid over interpreting the results. With that, it is 
fairly  consistent  that  patients  with  more  than  2/3 
p o s i t i v e   c o r e s   h a v e   a   h i g h e r   r i s k   o f   f a i l u r e   t h a n   p a-
t i e n t s   w i t h   a   l e s s e r   n u m b e r .   I n   t h e   c a s e   o f   G l e a s o n   7  
p a t i e n t s ,   i t   i s   p r o b a b l y   e n o u g h   t o   r e c o m m e n d   t r e a t-
ment, whereas if there a r e   < 1 / 3   p o s i t i v e   c o r e s   w i t h  
other  factors  negative,  it  might  give  impetus  to  ob-
serve. 
Other factors that have received intermittent in-
t e r e s t   i s   t h a t   o f   m i c r o   v a s c u l a r   d e n s i t y   a n d   p l o i d y .  
T h e i r   u t i l i t y   h a s   n o t   b e e n   w e l l   p r o v e n   ( 1 0 4 )   a n d   w e  
will mention them   o n l y   b r i e f l y   a s   t h e y   a r e   n o t   r o u-
tinely  obtained and are unlikely  to  be  available  to 
most clinicians. As new vessel formation is necessary 
for a cancer to grow, it is not uncommon to find in-
c r e a s e d   v e s s e l   f o r m a t i o n   i n   m a n y   t u m o r s .   T h e   d e g r e e  
of proliferati o n   i s   c o n s i d e r e d   b y   s o m e   t o   b e   a   m a r k e r  
of aggressiveness and it’s mediators such as vascular 
endothelial  growth  factor  (VEGF)  and  it’s  receptors 
such as VEGFR 1-3   a r e   t a r g e t s   o f   t h e r a p y   i n   m a n y  
cancers. In prostate cancer, it appears in some studies 
that high micro vascular density (MVD) is associated 
w i t h   p r o g r e s s i o n ,   i n   s o m e   c a s e s   s t r o n g l y   s o ( 1 0 5 -107), 
b u t   j u s t   a s   m a n y   o t h e r   s t u d i e s   s h o w   t h a t   w h e n   c o n-
sidered with multiple factors, it is not predictive on 
multivariate analysis. (108-111). 
Another  factor  that  received  some  attention  in 
the  pre-P S A   e r a   w a s   t h a t   o f   p l o i d y ,   b u t   i n   s p i t e   f a-
vorable  reports,  has  also  never  become  widely 
adapted.  Early  studies  showed  that  patients  with 
non-d i p l o i d   t u m o r s   w e r e   m o r e   l i k e l y   t o   f a i l ,   s o m e-
times with a dramatic difference (112), but except in 
rare  cases  the  effect  on  overall  survival  was  either 
n e g l i g i b l e   o r   m o d e s t .   ( 1 1 3 , 1 1 4 )   T h e   p a t i e n t s   t h a t   d i d  
the worst were those with anueploid tumors, but they 
only accounted for a small percentage of the patients 
(~10%) and in some   c a s e s ,   t h e r e   w a s   n o t   m u c h   d i f-
ference  between  the  diploid  and  tetraploid  patients 
( 1 1 5 ) .   I t   d i d   s e e m   t o   o f f e r   s o m e   d i f f e r e n t i a t i o n   f o r   p a-
t i e n t s   w i t h   l o w   g r a d e   t u m o r s   w i t h   a   9 4 %   1 0   y e a r   d i s-
ease  free  survival  for  diploid  versus  58%  for 
non-diploid. In high grade tumors the differentiation 
w a s   m o d e s t .   O t h e r   s t u d i e s   s h o w e d   n o   p r e d i c t i v e   s u r-
vival difference on ploidy analysis (116,117). While it 
is intriguing to consider that ploidy might help de-
termine risk, especially in the intermediate risk pa-
tients,  the  results have been inconsistent and incon-
clusive. 
Modeling factors 
As  evidenced  from  the  preceding  discussion, 
t h e r e   a r e   m u l t i p l e   f a c t o r s   t h a t   m a y   p r e d i c t   f o r   f a i l u r e  
a f t e r   p r o s t a t e c t o m y .   T h e   b e s t   r e c o g n i z e d   a r e   P S A ,  
Gleason  score  and  the  details  of  pathological  stage. 
Their effects are not totally independent of each other 
a n d   a t t e m p t s   h a v e   b e e n   m a d e   t o   c o r r e l a t e   t h e m   w i t h  
e a c h   o t h e r .   T h e   f i r s t   m o d e l s   w e r e   t h a t   o f   r i s k   g r o u p-
i n g .   O n e   o f   t h e   e a r l i e r   g r o u p i n g   o f   s u r g e r y   p a t i e n t s  
r e l i e d   o n   c l i n i c a l ,   r a t h e r   t h a n   p athological staging, so 
i s   a r c h a i c   b y   t o d a y ’ s   s t a n d a r d s .   ( 1 1 8 ) .   O v e r   t i m e ,   i t  
was thought that perhaps the predictive ability for an 
individual patient could be refined by improving on 
the risk clustering models. Attempts have been made 
to  incorporate  other  specific  prognostic  variables 
( s u c h   a s   m a r g i n   s t a t u s )   t o   i m p r o v e   t h e   p r e d i c t i v e   a c-
c u r a c y .   T h e s e   m o d e l s   a r e   d e v e l o p e d   f r o m   a   p o p u l a-
t i o n   o f   p a t i e n t s   w i t h   e s t a b l i s h e d   o u t c o m e s ,   s o   s t i l l   a r e  
subject to the uncertainties of the selection and exclu-
sion  bias’s  that  are  inherent  to  that  data.  Using  re-
gression  analysis,  multiple  factors  are  evaluated, 
w h i c h   s h o u l d   r e d u c e   t h e   e r r o r   o f   a n y   o n e   v a r i a b l e ,   b u t  
at the same time presents the risk of introducing other 
artifact.  Still,  the  nomograms  associate  continuous 
ris k   v a r i a b l e s   c o l l e c t i v e l y   a n d   t h e i r   p r o p o n e n t s  
m a i n t a i n   t h a t   t h e y   p r o v i d e   t h e   b e s t   e s t i m a t e   o f   p r o b-
ability of recurrence. As designed, individual predic-
t i v e   f a c t o r s   a r e   a s s i g n e d   a   r i s k   n u m b e r   ( b a s e d   o n  
proportional risk analysis) and when added together 
yie l d   a   t o t a l   n u m b e r   t h a t   c a n   b e   a s s o c i a t e d   w i t h   r i s k   o f  
f a i l u r e   a t   v a r i o u s   t i m e   p o i n t s .   T h e s e   n o m o g r a m s ,  
when  tested  against  the  population  used  to  design 
them are about 80% accurate (concordance incidence 
o f   0 . 8 ) .   T h e y   a r e   n o t   q u i t e   a s   r o b u s t   a g a i n s t   o t h e r  
populations, but appear to be an improvement over 
t h e   e a r l i e r ,   s i m p l e r   m o d e l s .   I t   i s   i n t e r e s t i n g   t o   l o o k   a t  
the assigned risk of the various factors (Table 5) and 
h o w   t h e y   d i f f e r   f r o m   s t u d y   t o   s t u d y   ( e v e n   t h o u g h  
some  of  the  nomograms  contain  some  of  the  same 
patients)(119-121).  The  points  themselves  are  arbi-
trary,  but  it  is  informative  to  look  at  their  potential 
proportional contribution to a given risk of failure (i.e. 
for a 70% risk at 10 years, 60% at 7 years, 50% at 5 
years and 30% at 2 years, a somewhat linear correla-
tion). The differences in percentage contribution of the 
factors  illustrates  that  even  in  these  more  sophisti-Journal of Cancer 2011, 2 
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cated models factors such as patient selection, factor 
s e l e c t i o n ,   a n d   l e n g t h   o f   f o l l o w   u p   h a v e   a n   i n f l u e n c e  
on their contribution t o   f a i l u r e .   F o r   e x a m p l e ,   i n   o u r  
earlier discussion, seminal vesicle involvement is an 
overwhelming predictor of failure, but as can be seen 
from the table, in all but one study shown, it wouldn’t 
e v e n   c o n t r i b u t e   m o r e   t h a n   2 0 %   o f   t h e   r i s k   i n   d e t e r-
mining the defined failure. The reminder here is that 
t h e   h i g h   r i s k   f a c t o r s   ( S V ,   m a r g i n ,   E C E ,   a n d  Gleason 
8-10)  often  cluster  together  to  some  degree  and  is 
w h a t   d r i v e s   f a i l u r e .   I t   p a y s   n o t   t o   b e   t o o   d o g m a t i c  
a b o u t   t h e   h i g h   r i s k   f e a t u r e s ,   b u t   t o   t r y   t o   t e a s e   o u t  
pati e n t s   w i t h   s o m e   o f   t h e s e   f a c t o r s   t h a t   m a y   h a v e   a  
l o w   r i s k   o f   f a i l u r e   ( i . e .   G l e a s o n   6   w i t h   p o s i t i v e   S V + )  is 
a c t u a l l y   a t   t h e   f r i n g e s   o f   t h e   d a t a   d u e   t o   s m a l l e r   p a-
tient numbers. T h e   p l a c e   t h a t   i t   m a y   b e   m o r e   i m p o r-
tant is in patients that are otherwise intermediate risk, 
s u c h   a s   o n e   w i t h   G l e a s o n   7   c a n c e r ,   a   P S A   o f   8 ,   E C E  
positive  and  margin  and  SV  negative.  This  patient 
w o u l d   b e   w e l l   b e l o w   o u r   a r b i t r a r y   r i s k   t h r e s h o l d  
b a s e d   o n   t h e s e   n o m o g r a m s ,   b u t   i f   h e   h a d   e x t e n s i v e  
E P E   o r   w a s   b l a c k ,   t h a t   m a y   b e   e n o u g h   to recommend 
treatment. 
 
Table 5: Contribution of individual nomogram risk factors on give risk of failure  
study  Stephenson119  Kattan120  Kattan 121  Schroeck97  Walz122 
Other factors not 
shown below 
Year of surgery  surgeon experience  Capsule invasion  Race, year of surgery, 
prostate weight 
None 
Points for failure 
threshold 
172 
Points for 10 yr failure 
>70% 
240 points for 
10 yr failure >70% 
200 points for 7 year failure 
>60% 
150 points # for 5 yr 
failure >50% 
 
115 points for 
2 yr failure >30% 
Risk factor 
points/% of points 
of failure thre-
shold 
         
LN+  11(6%)  35 (15%)  28 (14%)  ----  33(29%) 
ECE+  22(13%)  35(15%)  54(27%)*  10 (7%)  27(23%) 
SV+  23(13%)  31(13%)  26(13%)  28(19%)  49(43%) 
Mar +  10(6%)  35(15%)  34(17%)  35(23%)  23(20%) 
Gl 4-6  0(0%)  0(0%)  < 6(<3%)  0(0%)  0(0%) 
Gl 7  --  44(18%)  30(15%)  --  54(47%) 
3+4  14(8%)  --  --  16(11%)  -- 
4+3  33(19%)  --  --  40(27%)  -- 
Gl 8-10  47(27%)  88(37%)  --  49(33%)  100(87%) 
  --  --  8  46(23%)  --  -- 
  --  --  9  59(30%)  --  -- 
  --  --  10  72(36%)  --  -- 
PSA 2  72(42%)  13(5%)  65(33%)  15(10%)  2(2%) 
PSA 4  77(45%)  28(12%)  78(39%)  30(20%)  4(3%) 
PSA 5  80(47%)  35(15%)  82(41%)  34(23%)  5(4%) 
PSA 6  82(48%)  42(18%)  84(42%)  37(25%)  6(5%) 
PSA 8  83(48%)  53(22%)  88(44%)  43(29%)  9(8%) 
PSA 10  85(51%)  60(25%)  92(46%)  50(33%)  11(10%) 
15  87(51%)  71(30%)  93(47%)  58(39%)  16(14%) 
20  92(53%)  73(30%)  93(47%)  65(43%)  22(19%) 
30  93(54%)  77(32%)  94(47%)  73(49%)  33(27%) 
50  97(56%)  83(35%)  96(48%)  85(57%)  54(47%) 
*average of focal (51 pts) and extensive EPE (57 pts) 
#Used a 40 cc prostate which accounts for 35 points 
 
Summary 
The adjuvant radiation studies defined high risk 
patients as those with positive seminal vesicles (1-3), 
EPE(1-3), and/or positive margins(1-2). Those studies 
have unequivocally shown that radiation can reduce 
biochemical  failure.  The  SWOG  study  (1),  with  its 
m u c h   l o n g e r   f o l l o w   u p ,   h a s   s h o w n   b o t h   a   m e t a s t a s i s  
free and overall survival. Although the available data 
( 1 2 3 )   i n d i c a t e s   t h e   l o n g   t e r m   t o x i c i t y   o f   t h e   a d j u v a n t  
therapy  group  is  similar  to  the  observation  group, 
there is concern that not all the patients  that  would 
have qualified for the studies really have the recur-
rence risk to warrant immediate treatment. from the 
available literature, as reviewed above, it appears that 
patients  with  positive  seminal  vesicles,  or  Gleason 
8-1 0 ,   o r   P S A   >   2 0   n g / m l   h a v e   high  enough  risk  to 
w a r r a n t   t r e a t m e n t .   I n   a d d i t i o n ,   p a t i e n t s   w i t h   E P E   o r  
m a r g i n   p o s i t i v e   d i s e a s e   ( e s p e c i a l l y   i f   t h e y   h a v e   b o t h )  Journal of Cancer 2011, 2 
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and are Gleason 7 or higher warrant treatment. Fac-
t o r s   s u c h   a s   m u l t i f o c a l   o r   l a r g e   t u m o r s   a s   m e a s u r e d  
by biopsy core involvement add  further  support  to 
treating those patients up front rather than waiting for 
failure. 
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